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Abstract: The use of nanoparticles as a means of targeted delivery of therapeutics and imag-
ing agents could greatly enhance the transport of biologically active contents to specific target 
tissues, while avoiding or reducing potentially undesired side effects. Generally speaking, the 
oral route of administration is associated with good patient compliance, as it is convenient, 
economical, noninvasive, and does not require special training. Here, we review the progress of 
the utilization of nanodelivery-system carriers or stabilized solid-drug nanoparticles following 
oral administration, with particular attention on toxicological data. Mechanisms of cytotoxic-
ity are discussed and the problem of extrapolating knowledge to human scenarios highlighted. 
Additionally, issues associated with administration of drugs via the oral route are underlined, 
while strategies utilized to overcome these are highlighted. This review aims to offer a balanced 
overview of strategies currently being used in the application of nanosize constructs for oral 
medical applications.
Keywords: nanomedicine, oral route of delivery, nanomaterials, nano-stabilized solid drugs
Introduction
Nanotechnology is based on the understanding and exploitation of matter at the 
nanoscale (1–100 nm)1 in the integration of the nanostructures into larger systems for 
real-world applications. Nanoparticles (NPs) are approximately 1,000 times smaller 
than the average human cell. It is this small size (larger surface area) and other 
unique physiochemical properties that make them extremely desirable for medical 
applications.1–4 Over the last two decades, nanotechnology has gained prominence in 
modern biology, with the field of nanomedicine becoming one of the most prominent 
and vital.4 Nanomedicine allows for drug particles or delivery devices to be manipu-
lated at the nanoscale for improved delivery to different parts of the body, while at the 
same time retaining the valuable pharmacological properties of the drug.5 However, 
efficient drug delivery and the excellent release potential of these delivery systems 
may be hindered by possible untoward side effects. The unique properties that make 
NPs so desirable might also contribute to their potential toxicity.6 Therefore, safety 
evaluation of NPs with intended medical applications is of utmost importance.
In recent years, vast progress has been made in the synthesis of a variety of 
materials that can be used as nanovehicles (carbons, synthetic polymers, micelles, 
liposomes/vesicles, and drug–polymer polysaccharide conjugates, to name a few).7–10 
Currently, commercial nanomedicines are predominantly generated using two main 
strategies: a nanocarrier for drug molecules and stabilized solid-drug NPs (Figure 1). 
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These strategies have the potential to target a single cell 
type, and represent revolutionary tools for effective medi-
cine delivery. For example, NP surfaces can be chemically 
designed to influence site-specific drug delivery, as well 
as the kinetics of drug release.9,12 In addition to drug delivery, 
the discovery of quantum effects (size-dependent properties) 
that result in materials with specific emission, absorption, 
or light-scattering spectra has expanded potential applica-
tions in imaging and diagnosis.11 Further advantages of the 
use of NPs can include improved drug stability and longer 
shelf-life9 compared with traditional formulations. Each of 
these properties allows researchers to design and use NPs 
in medical applications that can enhance on conventional 
molecular approaches.13
Since drug delivery via the oral route is the focus of this 
article, it is important to consider potential local effects in 
the gastrointestinal tract (GIT). The GIT mucosa forms a 
dynamic physical and enzymatic barrier between the body 
and the luminal environment, which not only contains nutri-
ents but also is laden with potentially hostile microorganisms 
and toxins. Therefore, the GIT mucosa has evolved to allow 
efficient transport of nutrients across the epithelium while rig-
orously excluding passage of harmful molecules and organ-
isms. The exclusionary properties of the GIT mucosa present 
a complex set of problems for oral drug delivery.14 Another 
significant hurdle for oral delivery of many drugs is their 
inherently poor stability in the gastric environment.4,15,16 At 
the site of therapeutic absorption, NPs can be heavily affected 
in transport through the digestive tract, due to varying pH, 
transit time, pressure and bacterial content. The distinct 
features of each part of the digestive tract can introduce chal-
lenges to the application of therapeutics to the gut. Nonethe-
less, oral delivery is still the most common method for drug 
administration, due to its simplicity, noninvasive nature, and 
good patient compliance. Following ingestion, transloca-
tion of particles into and across the GIT mucosa can occur 
via four mechanisms: 1) endocytosis, through enterocytes, 
2) the M-cell-rich layer of Peyer’s patches (small-intestine 
lymphoid aggregates), 3) persorption, where particles can 
translocate through a “hole” left in the epithelium when 
enterocytes shed from the villous tip, and 4) the paracellular 
route, where NPs pass through weakened tight junctions of 
the epithelial cell layer.17–20 Moreover, NP translocation and 
interactions with tissues in the GIT can be influenced by size, 
morphology, hydrophilic–hydrophobic balance, and surface 
functionalization of the particles in question. For example, 
it has been suggested that negatively charged materials 
exhibit poor bioavailability, due to electrostatic repulsion and 
mucus entrapment.21 Once in the submucosal tissue, NPs can 
enter the lymphatics and the blood capillaries.12
The remainder of the manuscript examines the progress 
made in utilization of nanoscale carriers or stabilized solid-
drug NPs in medical applications following oral route of 
administration. The search criteria included a combination 
of the following terms: “nanomedicine”, “nanoparticles”, 
“nanomaterials”, “in vivo”, “liposomes”, “micelles”, “solid 
Figure 1 The two main common current strategies of generation of commercially available nanomedicines: nanocarrier for drug molecules and stabilized solid-drug 
nanoparticles.
Nanocarrier Nanoparticles
(drug)
Examples:
•  Micelles
•  Solid lipid
Nanoparticles
•  Polymers
•  Liposomes
•  Bilosomes
Examples:
•  Oleanolic acid 
•  Efavirenz
•  Paclitaxel
Purpose: 
•  Better absorption
•  Better distribution
•  Specific targeting
•  Longer half-life
•  Imaging
•  Diagnostics
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drug nanoparticles”, “oral route”, “oral exposure”, “oral 
administration”, “gastrointestinal tract”, “nanodelivery” 
“nanocarrier”, “nanovehicles”, “nanoconstructs”, “nano-
emulsions”, “adverse effects”, “toxicity”, “cytotoxicity”, 
“drug delivery”, “therapeutics”, “imaging”, “systemic”, 
and “Caco-2 cells”. The last literature search was conducted 
on August 24, 2017. Due to the inevitable limitations and 
exclusionary nature of any literature search, studies that did 
not include the search terms in the title or did not provide 
adequate information in the abstract might have been unin-
tentionally omitted. However, all attempts have been made 
to construct a comprehensive review and offer a balanced 
overview of the success of the current strategies for the use 
of nanosize constructs for oral medical applications. Due to 
the complexity of the topic being reviewed and discussed, we 
have intentionally aimed to make each study section compre-
hensive. Nevertheless, this does not include the methodology 
utilized for the manufacture of the constructs or loading and 
encapsulation efficacy of the active pharmaceutical ingredi-
ents. The review focuses on in vivo studies (predominantly 
in rodents), rather than in vitro experimentation, in order 
to capture the products that are potentially closer to market 
(assuming that initial screening and developmental work is 
conducted in vitro). As such, the reader could presuppose 
that the discussion focuses on “relatively safe” constructs. 
However, on occasion, this was not the case, ie, constructs 
loaded with chemicals designed to induce tumor-cell death. 
The review does not incorporate general NP oral toxicology/
biokinetics, but instead focuses on particles with intended 
medical applications. The main body of the review has been 
structured and divided based on World Health Organization 
ICD11 classification of disease22 and the intended therapeutic 
use of the nanomedicine.
Diseases of the digestive system
Helicobacter pylori infects more than half the world’s 
population and is responsible for most cases of inflamma-
tory gastritis, peptic ulcers, and gastric cancer.23 Currently, 
the standard treatment for H. pylori infection involves two 
antibiotics (clarithromycin combined with amoxicillin or 
metronidazole) and a proton-pump inhibitor, termed “triple 
therapy”.23 Unfortunately, bacteria-eradication rates with 
triple therapy have decreased significantly over the last 
20 years as a consequence of increased bacterial resistance 
to these antibiotics. Intriguingly, various free fatty acids, 
including linolenic acid (LLA) have been shown to contain 
antibacterial activity against a broad range of bacteria, 
including H. pylori. However, the in vivo inhibition of 
H. pylori by the free fatty acids is problematic, fundamen-
tally due to their poor solubility and the tendency for them 
to be oxidized and esterified in the GIT. To address these 
concerns, in a recent study LLA was packed inside a lipo-
some nanocarrier composed of l-α-phosphatidylcholine 
and cholesterol (LipoLLA; ~100 nm). First, the H. pylori 
bactericidal activity of LipoLLA was evaluated in vitro. The 
authors established the bactericidal concentration as 65 and 
80 µg/mL (LipoLLA and LLA, respectively). Interestingly, 
despite the strong bactericidal activity, the LipoLLA showed 
negligible toxicity to human gastric carcinoma cells follow-
ing 24-hour exposure up to concentrations of 900 µg/mL. H. 
pylori mainly resides within the adherent mucus layer, close 
to the epithelial surface of the stomach. Therefore, for effec-
tive antibacterial treatment, permeation of the drug across 
the mucus layer and its retention on the stomach wall are 
critical.23 To assess this, male C57BL/6 mice (~30 g) were 
exposed to 1.2 mg RhB-labeled LipoLLA for 4 or 24 hours 
via oral gavage. Quantification of gastric retention of the lipo-
some construct was noted as 69 µg at 4 hours posttreatment, 
decreasing to 34 µg at 24 hours. Next, in vivo therapeutic 
efficacy of LipoLLA was investigated in an H. pylori-infected 
C57BL/6 mouse model. Therapeutic efficacy was evaluated 
by enumeration and comparison of H. pylori in the stomachs 
of animals in different treatment groups and controls. The 
data demonstrated that in the mice treated with LipoLLA, the 
bacterial burden was 5.5×104 CFU/g in comparison to 108 in 
the control infected mice. Overall, the LipoLLA treatment 
reduced H. pylori burden ~2.5-fold compared to the control 
infected animals, whereas triple therapy reduced bacterial 
burden only ~1.5-fold. Additionally, mRNA expression of 
IL1β, IL6, and TNFα was significantly reduced in infected 
mice treated with LipoLLA (no acute inflammatory response 
to LLA liposome). Finally, the in vivo toxicity of the drug 
formulation was assessed in uninfected mice exposed to 
2.4 mg of the materials per day over a 5-day period. Gastric 
tissue treated with LipoLLA maintained an undisturbed 
structure with a clear layer of epithelial cells. Furthermore, 
similar to the negative control, there was no apparent increase 
in gastric epithelial apoptosis in LipoLLA-treated mice 
(TUNEL staining). The absence of any detectable gastric 
histopathology or toxicity within a 5-day treatment period 
suggested that orally administered LipoLLA is relatively 
safe at the specified dose. Overall, the data denote that the 
nanoformulation discussed in this study could hold potential 
for effective and safe treatment of H. pylori infections.23
In a 2015 study, the aim was to develop nanocon-
structs for better oral delivery of the acid-labile and poorly 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
98
.2
16
 o
n 
13
-D
ec
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7578
Kermanizadeh et al
water-soluble drug lansoprazole (Lpz), for gastric ulcer 
therapy.24 Acid-related disorders, such as peptic ulcer and 
gastroesophageal reflux disease, occur frequently in elderly 
individuals. Proton-pump inhibitors (eg, Lpz) are among 
the most effective drugs for the treatment of ulcer-related 
disorders. The two constructs were composed of positively 
charged Eudragit RS100 (~205 nm) or negatively charged 
poly(lactic-co-glycolic acid) (PLGA; ~220 nm). Male Wistar 
rats (300 g) were exposed to the formulations (5 mg Lpz/kg) 
via the oral route 1 hour after administration of ethanol was 
used to induce gastric ulceration. The animals were killed 
4 hours after NP administration. First, the data showed that 
the NPs were localized in both ulcerated and nonulcerated 
regions after oral administration. Moreover, the results 
indicated that the negatively charged particles adhered more 
readily to the ulcerated region, whereas the positively charged 
NPs predominantly localized in the nonulcerated region of 
the stomach. It was also demonstrated that all the drugs were 
eliminated within 6 hours after oral administration of Lpz 
solution (unformulated control), while the NP formulations 
showed sustained and prolonged Lpz concentrations up to 
24 hours. The elimination half-life and mean residence time 
for the Eudragit RS100 (4.6 and 8.2 hours, respectively) and 
PLGA (4.7 and 9 hours) were significantly longer than those 
for Lpz solution (1.4 and 1.9 hours). Finally, the ulcer-healing 
efficacy of Lpz NPs was evaluated at 7 days postexposure 
in ulcer-induced Wistar rats. The results showed that the 
gastric ulceration gradually healed within 1 week after oral 
administration of Lpz solution and Lpz NPs. The oral admin-
istration of Lpz solution healed 72% of gastric ulcers, while 
oral administration of the positively and negatively charged 
NPs healed 96% and 93% of gastric ulcers, respectively.24 
These results clearly demonstrate improved targeting and 
efficacy of Lpz when administered in an NP form compared 
to free drug.
Inflammatory bowel disease (IBD) is an umbrella of dis-
eases of which ulcerative colitis and Crohn’s disease are the 
most prevalent. If overt inflammation is not adequately sup-
pressed, chronic relapsing disorders of the GIT can develop 
into colorectal cancer.25 The current anti-inflammatory 
strategy consists of systematic administration of therapeutics 
at high doses, often associated with significant adverse side 
effects. CD98 is highly upregulated and expressed in colonic 
tissue with active colitis and Crohn’s disease.25 Additionally, 
the glycoprotein has been shown to be highly expressed 
on intestinal macrophages and plays an important role in 
macrophage activation. In recent years, RNA interference 
using siRNA has become a powerful tool for the silencing 
of disease-related genes. However, exploration of the thera-
peutic potential of siRNA has been extremely slow, due to 
the absence of carriers for targeted in vivo delivery.25 If not 
adequately controlled, the utilization of siRNA can be dan-
gerous, as it can easily cross tissue and cell barriers to enter 
the cytoplasm and cause the degradation of mRNA.25 In a 
novel study, a targeted CD98 siRNA (siCD98)-conjugated 
maleimide, urocanic acid, and polyethylene glycol (PEG) 
NP-delivery system was utilized for specific targeting of 
macrophages in the inflamed colon after oral administration.25 
The NPs were noted to be 150–250 nm in size. First, the 
cytotoxicity of the constructs was investigated in Colon-26 
cells and murine macrophages following a 6-hour (important 
to note that this is a relatively short exposure) in vitro treat-
ment (100 nmol/L siRNA). The authors did not observe any 
alteration in cell viability in response to the NPs. The tissue 
biodistribution of siCD98-functionalized NPs was investi-
gated using ex vivo tissue sections. The data demonstrated 
significant quantities of NPs accumulated in colonic epithelial 
cells after 6 hours of incubation. A T-lymphocyte-transfer 
mouse model of chronic colitis is considered the prototypical 
and best-characterized model of chronic colitis.25 The anti-
inflammatory effect of functionalized NPs was further 
investigated in this in vivo model. RAG-/- mice (animals 
that do not have mature lymphocyte populations, ~30 g) were 
injected with a flow-cytometry-purified CD4+CD45RBhigh 
T-cell population. This resulted in the characteristic tissue 
loss associated with IBD. The mice were exposed via gavage 
twice per week for 5 consecutive weeks, with or without the 
encapsulated siCD98-functionalized NPs (1 mg/kg siCD98 
or scrambled siRNA on each occasion). Oral administration 
of siCD98-loaded NPs significantly reduced weight loss at 
week 9 compared with untreated mice or mice treated with 
scrambled siRNA-loaded NPs. Furthermore, the data dem-
onstrated that myeloperoxidase (MPO) activity in the colon 
was increased in mice that had received a T-cell transfer. 
MPO levels were reduced by up to 65% in the siCD98-loaded 
NP-treated group compared with untreated animals (reduced 
inflammatory response). mRNA expression of TNFα, IL6, 
and IL12 was also decreased in the treated mice (60%, 80%, 
and 32% respectively), suggesting reduced inflammation. 
Finally, the study investigated whether orally delivered 
functionalized siCD98-loaded NPs could mitigate the clini-
cal manifestation of dextran sodium sulfate (DSS)-induced 
acute colitis in the mouse model. After 6 days, mice in the 
DSS control group had a body-weight loss of 18%, which 
was roughly twice that of mice in the treatment groups. More-
over, histopathological examination of colon tissue from the 
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DSS control group exhibited clear signs of inflammation, 
including epithelial disruption, goblet-cell depletion, and 
significant infiltration of inflammatory cells into the mucosa. 
In contrast, inflammation in tissue from siCD98-loaded NP-
treated mice was markedly lower. Overall, the study showed 
promising evidence of successful use of a siCD98-conjugated 
maleimide, urocanic acid, and PEG NP-delivery system as a 
means of effective IBD therapy.25
Another popular strategy in the treatment of IBD is 
the specific targeting of immune cells, which are highly 
abundant in inflamed regions of the GIT. This strategy is 
gathering popularity due to better understanding of the 
kinetics of increased adhesion of small-particulate drug 
carriers to inflamed tissue. This strategy was explored using 
surface-modified amorphous silica NPs. The NPs were 
covalently bound to 5-amino salicylic acid and character-
ized as ~150 nm in diameter. In these trials, male BALB/c 
mice (~25 g) were exposed to 2,4,6-trinitrobenzenesulfonic 
acid to induce colitis. During the treatment period, animals 
were orally exposed to doses up to 100 mg/kg body weight 
of salicylic acid in various formulations once daily for 
6 consecutive days. Animals were killed 24 hours after the 
last drug/particle administration. Histological examina-
tion of mice exposed to fluorescently labeled NPs showed 
selective accumulation in the inflamed tissue (quantitative 
analysis exhibited sixfold-higher adhesion of NPs to diseased 
tissue in comparison to healthy intestine). After induction 
of experimental colitis, clinical activity indices increased 
dramatically within 24 hours, indicating intestinal inflam-
mation. The decrease in clinical activity became visible on 
day 6 for both the NP- and free salicylic acid-treated mice. 
Similar to observations made regarding the clinical activity 
index, colon weight:length ratios after drug treatment were 
lower in NP-treated animals comparison to the colitis control. 
For both formulations, MPO activity was also significantly 
reduced, with higher therapeutic effects for NPs at 25 or 
50 mg/kg than free drug, even at 100 mg/kg. The selectivity 
of the NP formulation was further supported by the observa-
tion that locally applied modified NPs showed significant and 
therapeutic efficiency.26
As indicated, such IBDs as ulcerative colitis and Crohn’s 
disease are both characterized by an overexpression of 
inflammatory cytokines and mediators, namely TNFα, IL6, 
and NFκB.27 In a recent study, raloxifene (potent suppres-
sive of the transcription of NFκB) was incorporated into 
nanomicelles (~70 nm) composed of poly(styrene-co-maleic 
acid).28 These micelles were used as a delivery platform to 
improve raloxifene’s water solubility, protecting it from 
first-pass metabolism and efflux mechanisms. In this study, 
female BALB/c mice (~20 g) were administered with 3% 
DSS in drinking water for 14 days to induce colitis. At day 7, 
the mice were orally treated, either by free raloxifene or the 
micelle formulation, for 3 days with a dose equivalent to 
5 mg/kg. The authors showed that compared to the con-
trols, weight gain was clearly visible after 14 days in the 
raloxifene-treated animals. Additionally, the average colon 
length of DSS-treated mice was 7.4 cm compared with 12.3 
and 11.5 cm in free raloxifene- and nanomicelle-treated mice 
respectively. Histological examination of the DSS-treated 
mice indicated highly inflamed colon tissue with extensive 
mononuclear cell infiltration. Colon tissue obtained from 
both free raloxifene- and micelle-treated groups clearly 
demonstrated tissue recovery. Finally, analysis of plasma 
collected from the DSS-treated mice showed increased IL6 
levels of 194% compared to unexposed mice. This was 
reduced to 88% and 53% following administration of the 
free-drug suspension and nanoformulation compared to the 
DSS-treated animals, suggesting that the micellar delivery 
system was more efficient in the reduction of inflammatory 
cytokines.28
Diseases of the liver
Oleanolic acid is a naturally derived triterpene used clini-
cally in the treatment of hepatitis (inflammatory disease of 
liver, autoimmune or secondarily induced by drugs, toxins, 
or alcohol).29 However, like many other hydrophobic drugs, 
it has very poor bioavailability. In a 2005 trial, oleanolic acid 
nanosuspensions (~285 nm spheres) were prepared and uti-
lized in a male Kunming mouse model (~20 g). First, carbon 
tetrachloride (CCl
4
) was utilized to induce hepatocellular 
damage in the exposed mice, evidenced by increased serum 
ALT and hepatic malondialdehyde content. Oral pretreatment 
with 100 mg/kg oleanolic acid before CCl
4
 administration led 
to a 61% and 43% reduction in ALT rise in serum and liver 
malondialdehyde content, respectively. After pretreatment 
with oleanolic acid NPs, ALT values were 80% and 66%, 
respectively. The higher absorption of nanosize oleanolic 
acid may account for the enhanced hepatoprotective proper-
ties of oleanolic acid NPs.29
Norcantharidin is a demethylated analog of cantharidin 
that is very effective in hepatic carcinoma chemotherapy. 
However, its clinical applications are limited, due to some 
serious side effects, which include nephrotoxicity and 
inflammation.30 In a recent study, male and female Sprague 
Dawley rats and CD1 mice were orally exposed to 5 mg/kg 
of a formulation containing polyvinylpyrrolidone-coated 
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norcantharidin chitosan (CS) NPs (~140 nm). The data 
showed that oral administration of the NPs had greater bio-
availability of around 173% in comparison to the traditional 
drug formulation. After oral dosing, total residue concentra-
tions in the tissues were highest at 1–3 hours and mostly 
distributed to the liver and the kidneys. The quantity of the 
parent drug eliminated in the feces of the nanoformulation 
was 32 times greater than that of the traditional drug (reduced 
toxicity in hepatic cells due to decreased norcantharidin 
buildup).30
An active ingredient of Rabdosia rubescens, oridonin has 
been used for the treatment of hepatic carcinomas.31 How-
ever, poor aqueous solubility, low oral bioavailability, and 
rapid clearance limit clinical application of the compound. 
The principle that wheat-germ agglutinin-modified lipid–
polymer hybrid NPs (WGA-LPNs) can promote cellular 
uptake after oral delivery via receptor-mediated endocytosis 
was used to develop a delivery system for improved oral 
delivery of the prodrug. The liposomes were prepared in 
an aqueous phase containing 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine, PEG2,000, and phosphatidylcholine 
(Lipoid S100) (~120 nm). For pharmacokinetic analysis, 
male Sprague Dawley rats (~220 g) were administered via 
oral gavage different formulations at a dose of 10 mg/kg for 
up to 24 hours. In order to assess the efficacy of the delivery 
system, a tumor-xenograft model was established by inocu-
lation of HepG2 cells subcutaneously into the right-armpit 
region of male BALB/c nude mice (~20 g). Once tumor 
volume reached approximately 200 mm3, the animals were 
administered formulations every 2 days via oral gavage for 
24 days 5-fluorouracil (5FU) solution (22.5 mg/kg), oridonin 
suspension (7.5 mg/kg), LPNs, or WGA-LPNs (7.5 mg/kg). 
Tumor volume and body weight were recorded every 2 days 
during treatment. The data showed that the relative serum 
bioavailability of WGA-LPNs increased ninefold compared 
with free suspension. Next, efficacy evaluation showed the 
modified liposome-delivery system to be highly effective 
against the tumor. The therapeutic properties (a reduction 
in tumor volume and reduced body-weight loss) of the lipo-
somes were significantly higher than both the free oridonin 
formulation and 5FU. Overall, the data demonstrated that 
the liposome formulation had great potential as an oral 
delivery vehicle for oridonin, due to its ability to permeate the 
intestinal mucus layer, allowing for significantly improved 
pharmacokinetics, and effective antitumor activity.32
Diseases of the circulatory system
Nisoldipine is a calcium-channel blocker used to treat 
hypertension.33 However, the oral bioavailability of the drug 
is only about 5% of the overall administered dose, due to very 
low aqueous solubility and high presystemic metabolism.34 
In an attempt to improve the solubility and oral bioavail-
ability of the compound, 100 nanosize compositions with 
varying concentrations of different oils (25%–70% w:w), 
surfactants (30%–75% w:w), and cosurfactants (0–25% w:w) 
were prepared. From the initial panel, two nanocarrier 
formulations were selected as potential candidates for effec-
tive drug delivery based on solubility, stability over time, 
droplet size (one of the most important characteristics for 
stability evaluation and in vivo absorption), particle-size 
distribution, and negative ζ-potential. The two nanocarriers 
were termed ACP19 (Acrysol EL135 60%, PEG 30%, and 
Capmul MCM 10%; ~100 nm) and PCT08 (peppermint oil 
60%, Capmul MCM 35%, and Transcutol 5%; ~700 nm). 
The bioavailability of nisoldipine was investigated in male 
Wistar rats (~250 g). The two formulations and free drug 
suspension were administered to the animals at a dose of 
5 mg/kg by oral gavage. The data demonstrated that the 
nisoldipine plasma concentrations in Wistar rats treated with 
self-emulsified formulations were significantly higher than 
those treated with the drug in suspension. The bioavailability 
of ACP19 and PCT08 was 2.5- and 2.2-fold greater than the 
drug in suspension, respectively. Moreover, the maximum 
nisoldipine concentration in plasma of ACP19 and PCT08 
was 76 and 69 ng/mL respectively, compared to the drug 
in suspension (23 ng/mL). The study concluded that the 
optimized ACP19 formulation enhances the solubility and 
bioavailability of nisoldipine.34
Olmesartan medoxomil is a potent angiotensin II receptor 
antagonist clinically used for the treatment and management 
of hypertension.35 However, the drug exhibits low and incon-
sistent oral bioavailability in humans, primarily due to its high 
lipophilicity. In a recent study, a cationic self-nanoemulsifying 
oily formulation composed of oleic acid (32 mg/mL), Tween 40 
(55 mg/mL), and Transcutol HP (44 mg/mL; ~50–100 nm) 
was manufactured to enhance the oral bioavailability of the 
cargo. In these experiments, unisex Wistar rats (~300 g) were 
orally exposed to the formulation at doses of 20 mg/kg for 
up to 72 hours. Pharmacokinetic data exhibited significantly 
superior oral bioavailability, both in terms of extent and rate of 
absorption by the nanoformulation compared to the free drug 
suspension (4.9-fold improvement in plasma concentrations 
and 0.96-fold reduction in time to maximum concentration).35
Simvastatin (Smv) is an inhibitor of 3-hydroxy-3-methyl 
coenzyme A reductase, which can lower plasma cholesterol 
concentrations.36 The compound is currently used clinically 
to treat hyperlipidemia and various cardiovascular diseases.36 
However, Smv has extremely poor water solubility, resulting 
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in oral bioavailability of ,5%. In a 2015 study, two nano-
size formulations were manufactured to encapsulate Smv to 
enhance its oral bioavailability. These included a liposome 
composed of soybean lecithin and cholesterol (~110 nm) 
and an Smv-polyamidoamine dendrimer (~10 nm). Male 
Sprague Dawley rats with a body weight of 150 g were orally 
administered Smv 140 mg/kg body weight for 10 hours. The 
data showed that the maximum plasma concentrations of 
Smv in the dendrimer-complex- and the liposome-treated 
groups were 2.2 and 3.8 times higher, respectively, com-
pared to the free Smv-exposed animals. Furthermore, both 
the dendrimer and liposome formulations dramatically 
enhanced the oral bioavailability of Smv (2.5- and 3.7-fold 
increase, respectively). The study provided evidence of an 
effective and complementary strategy for the improved oral 
administration of Smv.36
Hydroxysafflor yellow A (HSYA) is the active component 
of Carthamus tinctorius, a plant routinely utilized in Chinese 
medicine for treatment of various cerebrovascular and car-
diovascular diseases.37 HSYA has also been demonstrated to 
have a substantial antagonistic effect on the platelet-activating 
factor receptor, as well as promising neuroprotective action. 
However, the compound is extremely hydrophobic with low 
oral bioavailability. In order to increase oral absorption, the 
drug was encapsulated in a caprylic/capric triglyceride bean-
phospholipid NP construct (~50 nm). Male Sprague Dawley 
rats (~200 g) were orally exposed to 25 mg/kg of the NPs 
over a period of 24 hours. The data demonstrated that drug 
plasma concentrations were enhanced 23-fold following 
oral administration of HYSA NPs compared to traditional 
HSYA solution.37
Curcumin is known to contain beneficial properties, 
which include but are not limited to anti-inflammatory, 
anticoagulation, antithrombus, antioxidant, and antiangio-
genic attributes.38 However, curcumin has extremely poor 
oral bioavailability, which has hampered its utilization in 
more advanced clinical formulations. In a 2012 investiga-
tion, a polybutylcyanoacrylate-NP system was introduced 
to improve its oral bioavailability. The nanostructures were 
found to be in the range of 40–400 nm with a mean size of 
100 nm. The pharmacokinetics of NPs were addressed in a 
male Wistar rat model (~200 g) following oral administra-
tion of 50 mg/kg of the formulation. The data demonstrated 
that the polybutylcyanoacrylate NPs enhanced the relative 
bioavailability of curcumin more than eightfold compared 
to the traditional suspension, with ileum and colon being the 
main absorption sites in the GIT.39
In another study, an NP construct composed of curcumin 
and negative polyanion tripolyphosphate (~110 nm) was 
developed to increase the solubility, permeability, dissolu-
tion, and bioavailability of the polyphenol. The pharmacoki-
netic properties of the NPs were compared with a curcumin 
suspension (dissolved in 0.5% aqueous solution of sodium 
carboxymethylcellulose) in Sprague Dawley rats (~300 g) 
after an oral dose of 100 mg/kg. The authors showed the 
relative bioavailability of curcumin NPs was 450% of the free 
chemical in suspension. Interestingly, there was no significant 
difference in plasma availability between the two formula-
tions, with total clearance at around 12 hours postexposure. 
The significantly augmented absorption was explained by 
increased affinity between the NPs and the epithelial cell 
membrane in the GIT, due to better dispersibility of curcumin 
in the NP formulation.40
In a similar study, PLGA and polyvinyl alcohol (PVA)-
based NPs (~190 nm) were utilized to improve the bioavail-
ability of curcumin. Here, male Sprague Dawley rats (~150 g) 
were exposed to 100 mg/kg of the NPs by oral gavage. 
Pharmacokinetic data demonstrated that NP encapsulation 
increased the intestinal absorption of the polyphenol and was 
predominantly available as metabolite curcumin glucuronide 
in plasma. Interestingly, the analysis of the curcuminoids in 
the liver and kidneys 1.5 hours postexposure did not show 
any increased accumulation in these organs for the NP 
formulations.41
Drug adsorption into a nanostructured carrier with a large 
surface area might be a useful approach for improving the 
dissolution rate and absorption of poorly water-soluble drugs. 
In addition, the use of hydrophilic or pH-sensitive polymers 
might further enhance the biological efficacy of poorly 
water-soluble drugs. In a 2013 study, an amphiphilic poly-
meric solubilizer (Soluplus) was applied to a colloidal silica 
nanomatrix (termed SCCSN) for enhanced solubility and 
oral absorption of three water-insoluble drugs (atorvastatin 
calcium [an HMG-CoA reductase inhibitor], dutasteride 
[a 5α-reductase inhibitor], and sorafenib tosylate [an inhibitor 
of several tyrosine protein kinases]). The matrix was char-
acterized using scanning electron microscopy and showed a 
primary particle size of about 10 nm. Male Sprague Dawley 
rats (~200 g) were exposed via the oral route to 2 mg/kg of 
the complex. All SCCSNs had rapid dissolution rates, with all 
three drugs reaching maximum solubility within 30 minutes 
postexposure. For atorvastatin calcium, dutasteride, and 
sorafenib tosylate, the maximum saturated concentration of 
SCCSN was significantly higher than that of the unloaded 
version of each drug, with approximately 2.8-, 326- and 
46-fold increases in solubility, respectively. The data sug-
gested that the SCCSN system could be a promising approach 
to improve oral absorption of poorly water-soluble drugs. 
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It is important to state that no toxicity data were provided 
in the study.42
Diabetes mellitus
Oral delivery of insulin is still a challenge, due to rapid enzy-
matic degradation in the stomach, inactivation and digestion 
by enzymes in the intestinal lumen, and poor permeability 
across the intestinal epithelium because of its high molecu-
lar weight and lack of lipophilicity.43 The oral delivery of 
insulin can prove highly advantageous, as it transports the 
drug directly to the liver, its primary site of action via portal 
circulation. In an interesting study, insulin solid-lipid NPs 
(SLNs) modified with stearic acid–octaarginine (~160 nm) 
were prepared to improve the stability and bioavailability of 
the hormone. SLNs have a large specific surface area of phys-
iologically compatible lipid matrix and can protect against 
the harsh GIT environment, principally by encapsulation of 
proteins within the nanostructures. Furthermore, the carrier 
itself can be taken up by epithelial cells or the lymphoid 
tissues in Peyer’s patches. In this experiment, NPs with and 
without stearic acid–octaarginine were administered to the 
duodena of fasted diabetic Sprague Dawley rats (~200 g) at 
an insulin dose of 25 IU/kg. The standard insulin solution 
as a control showed no hypoglycemic effect. The unmodi-
fied SLNs had maximum blood glucose lowering of 73% 
at 2 hours, while the stearic acid–octaarginine NPs showed 
significant hypoglycemic effect: maximum blood glucose 
lowered to 30% at 1.5 hours.43
Due to its important role in glucose metabolism, GLP1 
and its derivatives have been recognized as drug candidates 
for the treatment of type 2 diabetes.44 However, GLP1 
is rather poor in crossing the intestinal epithelium and 
extremely susceptible to enzymatic degradation. In a 2012 
study, a silica-based (silica particles) and Eudragit (polymer 
to enable delivery) pH-sensitive nanomatrix (~300 nm) 
was prepared in an attempt to provide a strategy for oral 
delivery of the peptide prodrug. In these experiments, male 
Sprague Dawley rats (~200 g) were orally administered 
with the constructs at a dose of 1 mg/kg. In a subset of the 
trials, the hypoglycemic efficacy of the formulation was 
investigated in a group of animals receiving 2 g/kg glucose 
intraperitoneally after oral exposure to the NPs. The data 
showed that oral administration of the NPs had a significant 
hypoglycemic effect that was comparable to the same dose 
administered via the intraperitoneal route (77% in com-
parison with the intraperitoneal GLP1 group). Next, it was 
demonstrated that the bioavailability of the oral nanomatrix in 
comparison to the intraperitoneally injected GLP1 was 36%. 
Finally, toxicological assessment of oral administration of 
NPs revealed no histological abnormalities in the stomach, 
duodenum, jejunum, ileum, cecum, or colon. This seems 
to suggest no associated acute GIT injuries or morphology 
changes following NP exposure at the administered dose. 
Overall, the study provided evidence of the manufacture 
of a novel pH-sensitive (important for drug release) GLP1 
nanomatrix with high hypoglycemic efficacy and very little 
toxicity, which could prove beneficial as an oral antidiabetic 
agent for the treatment of type 2 diabetes mellitus.45
Exendin 4 is an incretin (hormone that stimulates insulin 
production) analog found in lizard saliva and belongs to a 
new class of antidiabetic drugs. Exenatide is a synthetic ver-
sion of exendin 4 that mimics the glycoregulatory activity 
of the mammalian hormone GLP1.46 To date, the only route 
of administration is subcutaneous injection. Oral delivery of 
exenatide would clearly be beneficial to diabetic patients, as 
it would improve patient compliance and alleviate pain and 
discomfort from repeated dosing. In a recent study, goblet-
cell-targeting sodium triphosphate and CS NPs (~150 nm) 
were manufactured to encapsulate exenatide. In these 
experiments, two animal models were utilized. First, a male 
Sprague Dawley rat model (~250 g, 50 µg/kg) was used to 
analyze the pharmacokinetic profile of oral exposure to the 
drug. Additionally, a diabetic male mouse model (30 µg/kg) 
was utilized to assess the pharmacological effects of the 
exenatide-loaded NPs. The data demonstrated that the oral 
administration of modified CS NPs resulted in maximum 
plasma levels of the drug – 2,238±156 pg⋅h/mL with relative 
bioavailability of 6.5% – 1.7-fold higher than unmodified 
CS NPs. Moreover, in vivo fluorescence imaging of fluo-
rescein isothiocyanate-labeled exenatide NPs at 30 minutes 
and 1, 2, or 4 hours showed significant accumulation of the 
particles in the stomach, small intestine, and liver. Finally, 
the pharmacological effects of the drug-loaded NPs displayed 
comparatively high hypoglycemic effects at 30 minutes and 
1 hour postadministration. The data suggested that the CS 
NPs could prove to be highly beneficial in type 2 diabetes 
patients.47
In a recent study, polylactic acid (PLA)-b-Pluronic 
(P85)-b-PLA vesicles (~180 nm) were developed as a novel 
carrier for oral insulin delivery. In these experiments, male 
Kunming mice (~25 g) were fasted for 15 hours before 
administration of three intraperitoneal injections of alloxan 
to induce diabetes. The diabetic mice were exposed to insulin 
vesicles at doses of 50, 100, and 200 IU/kg. For comparison, 
free insulin (5 IU/kg) was injected subcutaneously into the 
diabetic mice. Oral administration of insulin-loaded NPs 
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resulted in minimum blood glucose concentration after 
2.5 hours, which was 15% of the initial glucose level. Fur-
thermore, the blood glucose concentration increased slowly 
to 32% of initial blood concentrations after 10.5 hours and 
was maintained for an additional 14 hours (32.5% of initial 
blood glucose concentration at 24.5 hours). In contrast, the 
minimum glucose concentration (11% of initial glucose 
level) was observed 2.5 hours after subcutaneous injection 
of free insulin. This indicated that the hypoglycemic effect 
for the oral administration of vesicles was maintained over 
a longer time than for the standard subcutaneous injection 
of free insulin.48
Neoplasms
Oral chemotherapy is an attractive proposal for many reasons, 
one of the most important being the avoidance of injections 
and improved patient compliance and quality of life. In addi-
tion, it allows for prolonged exposure of anticancer drugs 
to cancerous cells by maintaining effective plasma drug 
concentration, thus increasing drug efficacy and reducing 
adverse effects, as well as facilitating chronic treatment 
regimens. However, oral delivery of anticancer drugs is 
extremely challenging, due to GIT physiological barriers: 
presystemic metabolism, low aqueous solubility, and poor 
intestinal membrane permeability.
Docetaxel (Dtx) is a potent anticancer drug utilized in 
the treatment of breast cancer, non-small-cell lung cancer, 
prostate cancer, and gastric adenocarcinomas.49 Currently, 
an intravenous formulation of Dtx is commercially avail-
able. However, it contains high concentrations of Tween 
80, which has been associated with severe hypersensitivity 
reactions.50 Oral chemotherapy would have some appar-
ent advantages, including offering a noninvasive route of 
administration and being considerably more cost-effective. 
In addition, oral administration of anticancer drugs might 
provide a prolonged systemic exposure profile with smaller 
fluctuations in drug concentrations, which may lead to lower 
toxicity and improved efficacy. In a recent study, Tween 80 
or d-α-tocopheryl PEG1,000 succinate (TPGS 1000) surface-
modified tristearin liposomes (~200 nm) were prepared and 
evaluated for their pertinence as oral delivery systems for Dtx 
in male Sprague Dawley rats. The animals were exposed to 
the liposomes via oral gavage (20 mg/kg). The data demon-
strated the intestinal absorption and relative oral bioavail-
ability of Dtx was significantly improved in TPGS-emulsified 
liposomes, in all probability due to better inhibition of drug 
efflux. Next, the toxic potential (pathological alterations) of 
Dtx-loaded liposome exposure was evaluated in the intestinal 
mucosa of the exposed animals. The investigators did not 
observe any evidence of tissue damage in the sections of the 
jejunum examined.51
As touched upon, Dtx is considered one of the most 
important antitumor drugs in clinical use. However, similar 
to numerous other drugs discussed in this review, it has 
very poor solubility in water. To address this and other 
related issues associated with the use of the commercially 
available formulation (currently administered via the intra-
venous route) in a 2012 study, Dtx-loaded lecithin NPs were 
manufactured (~360 nm). In this set of trials, male Sprague 
Dawley rats (~250 g) were orally exposed to 20 mg/kg of 
the drug-loaded NP formulation for up to 12 hours. The 
maximum plasma concentration of drug from the NPs was 
fourfold higher than that of the Dtx solution. Additionally, 
maximum plasma concentration was reached at later time 
points for the NP formulation compared to the free drug, 
suggesting a sustained-release profile. The authors postulated 
that the increased oral bioavailability of Dtx in the NPs might 
have been attributable to several factors. First, the uptake 
of NPs may have been enhanced by the relatively small 
particles, particularly in gut-associated lymphoid tissue, 
whereby they could potentially have bypassed the liver first-
pass metabolism. Second, the sustained-release property of 
the NPs increased the circulation time of the drug, which 
prolonged Dtx residence in systemic circulation. Third, 
encapsulation of Dtx into the NPs might have protected the 
drug from degradation. Finally, the lecithin lipids might 
have augmented permeation of the prodrug through the 
intestinal membrane.52
To improve the oral bioavailability of doxorubicin (Dox; 
a class of chemotherapy drug [anthracyclines] that functions 
by slowing or stopping growth of cancer cells by blocking 
type 2 topoisomerase 2), polymeric nanomicelles composed 
of hyaluronic acid-linked β-cyclodextrin were developed in 
a recent study. The micelles were then coated with CS to 
increase the biocompatibility and biodegradability of the 
construct. In most physiological fluids, CS is positively 
charged, which can elicit adhesion to GIT mucus. Particle 
size was measured by transmission electron microscopy 
(TEM) and dynamic light scattering and was around 250 nm, 
with particles stable up to 30 days. Pharmacokinetic inves-
tigation of the micelles in a male Wistar rat model (~250 g) 
following oral administration of the composites containing 
40 mg/kg Dox demonstrated that CS-coated nanomicelles 
increased maximum plasma concentration up to fourfold. 
Furthermore, CS-coated micelles were retained longer in the 
GIT (~3 hours in comparison to ~2 hour for Dox solution). 
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This study clearly demonstrated the benefits of the use of the 
nanomicelles in terms of biodegradability, biocompatibility, 
and bioadhesion as a means of improving the oral bioavail-
ability of anticancer medication.53
Paclitaxel (Ptx) is highly efficacious drug in the treat-
ment of non-small-cell lung cancer, breast cancer, ovarian 
carcinoma, and head and neck cancers. Despite its efficacy, 
the traditional methodologies for drug delivery are asso-
ciated with severe side effects, such as hypersensitivity, 
nephrotoxicity, and neurotoxicity.54 In a recent investigation, 
Ptx-stabilized Pluronic F127 nanocrystals (~150 nm) were 
used in an attempt to reduce the side effects associated with 
traditional drug administration. In these studies, 4T1 cells 
(murine breast cancer) were subcutaneously injected into 
the stomachs of BALB/c mice (~20 g), with tumor volumes 
of the xenograft mice being monitored every other day. 
In the oral administration studies, the nanocrystals were 
administered on a daily gavage regime. First, the toxicity 
of the formulations was assessed in intravenously injected 
animals. The administration of Ptx in Cremophor (commer-
cially available formulation) resulted in six of six mice dying 
following exposure to 30 mg/kg. However, no mortality was 
observed up to doses of 60 mg/kg for the Ptx nanocrystals. 
Following the oral administration of the drug, no antitumor 
activity was observed in mice treated with the commercially 
available Ptx suspension. Nevertheless, oral administration 
of the nanocrystals significantly inhibited tumor growth. 
Unsurprisingly, oral administration of the drug resulted in 
less efficacy compared to the intravenous route. Overall, the 
data suggest that the nanocrystals achieved higher efficiency 
of drug loading, with few side/toxic effects in comparison 
to the currently commercially available Cremophor-loaded 
formulations following oral exposure.55
Unfortunately, most anticancer drugs have very poor 
oral bioavailability, as is the case for Ptx. In a 2010 study, 
vitamin E TPGS 1000-emulsified PLGA NPs were manu-
factured for oral delivery of Ptx. The materials characterized 
were spherical and around 300 nm in diameter. First, in a 
series of in vitro cytotoxicity experiments, MCF7 human 
breast cancer cells were exposed to the Ptx-loaded NP 
suspension or a commercially available formulation at drug 
concentrations of 0.025–50 mg/mL for 24–72 hours. The data 
demonstrated that compared with the commercially available 
formulation of the same dose, Ptx in NPs was more effective 
for antiproliferative activity on MCF7 cells (though these 
differences were relatively small). Next, the in vivo pharma-
cokinetics of Ptx in either its current clinical formulation or in 
NPs were investigated in male Sprague Dawley rats (~250 g) 
at a dose of 10 mg/kg of the prodrug. The authors showed 
that the drug concentration in plasma for the commercially 
available formulation was rather low, with an oral bioavail-
ability of only 2.4%. In contrast, for the drug in the TPGS 
1000-emulsified NPs, blood concentration was significantly 
increased to 8,510 ng⋅h/mL, which was around tenfold higher 
(24%). Finally, the sustainable therapeutic time for the NPs 
was dramatically increased to 88 hours, around 13 times 
that of the commercially available formulation. Overall, 
the data demonstrated the formulation of emulsified PLGA 
NPs was a promising approach for oral Ptx administration. 
However, it should be stated that intravenous injections are 
the primary administration route for the commercially avail-
able formulation in current anticancer strategies, and hence 
direct comparison between the two delivery formulations is 
not necessarily appropriate.56
In a 2012 study, a soy phosphatidylcholine–glycerol 
dioleate-based liquid crystalline NP system (~85 nm) was 
developed as an oral delivery platform for Ptx. In vivo 
pharmacokinetics of the drug formulations were investi-
gated in Sprague Dawley rats after oral administration of a 
commercially available drug and loaded NPs at a Ptx dose 
of 5 mg/kg for up to 24 hours. The data showed that plasma 
concentrations of the drug were 2.1-fold higher for the NPs 
compared to the commercially available Ptx. Furthermore, 
absolute bioavailability of Ptx delivered by the NP carrier 
and the traditional formulation was calculated as 13% and 
6.5%, respectively. The findings of this study suggested that 
the NP-delivery system may be an auspicious candidate for 
improving the oral bioavailability of the prodrug.57
N
3
-O-toluyl-fluorouracil (TFU), a prodrug composition of 
5FU, has demonstrated promising in vitro and in vivo antican-
cer efficacy.58 However, the drug is extremely hydrophobic 
and has poor bioavailability after oral administration. To 
address these issues in a recent study, TFU-loaded cationic 
liposomes were utilized to enhance the oral bioavailability 
of the drug. The liposomes were manufactured from soy leci-
thin and shown to be around 180 nm. In these experiments, 
the biodistribution of the formulations was investigated in 
a Kunming mouse model (~28 g). Animals were exposed 
to 50 mg/kg TFU liposomes via the oral route. The authors 
showed that the GIT bioavailability of cationic TFU lipo-
somes was doubled compared to the drug in suspension. The 
enhanced monodispersion of the liposomes in the GIT was 
suggested as the primary contributing factor to the increased 
levels of drugs in the circulation.59
A series of self-assembled nanostructures with prodrug 
conjugates based on commercially available capecitabine 
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(N-pentyloxycarbonyl-50-deoxy-5-fluorocytidine) were 
developed by substituting the pentyl group at the N4 posi-
tion with three different hydrophobic alkyl chains: palmityl 
(5FC
Pal
; 700 nm), oleyl (5FC
Ole
; 255 nm), and phytanyl 
(5FC
Phy
; 164 nm). These substitutions were intended to 
enhance the efficacy of the commercially available formula-
tion. The efficacy of the new formulations was evaluated in 
female BALB/c mice (~20 g) injected with 4T1 cells into 
the third mammary fat pad. Daily drug treatment was com-
menced at 3 days postinoculation. Animals were exposed 
to 1 mmol of the nanoconstructs or the commercially avail-
able drug for 6, 10, 13, or 17 days via oral gavage and the 
size of developed tumors measured. The data demonstrated 
that after 17 days, the 5FC
Ole
-treatment group possessed 
significantly smaller tumors than all other treatment groups 
(around a fifth the size of the tumors in both the 5FC
Phy
- 
and capecitabine-treatment groups and a tenth the size of 
tumors in the untreated control group). Interestingly, spleens 
in the 5FC
Ole
-treatment group were normal in size, while 
spleens from the other treatment groups were significantly 
enlarged. This is indicative of a strong inflammatory response 
induced by the tumor. The data from this study provided 
convincing evidence for the significant potential of 5FC
Ole
-
modified NPs delivered orally in the treatment of progressive 
breast cancer.60
The Notch signaling pathway is crucially important in 
the regulation of the development and tissue homeostasis 
of stem cells and known to be deregulated in inflammatory 
intestinal disease and colon cancer. The majority of clinical 
studies aiming to inhibit Notch have principally been focused 
on the use of γ-secretase inhibitors, which impede the pro-
teolytic processing and activation of the Notch receptor.61 
In a recent study, surface-modified silica NPs were manu-
factured and utilized for the specific delivery of N-[N-(3,5-
difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester 
(DAPT; γ-secretase inhibitor) to overcome challenges in 
oral administration caused by drug degradation at low pH 
and reduced permeability through the mucus layers. In the 
study, silica NPs were surface modified with polyethylen-
imine (PEI), PEG, and folic acid (FA) (~400 nm) with the 
aim of better facilitating binding to negatively charged cells 
and reducing uptake by the reticuloendothelial system. First, 
in vitro cytocompatibility of all produced NPs was assessed 
in colon cancer Caco2 cells for 48 hours and demonstrated 
particles to be atoxic up to 50 µg/mL. Oral exposure to the 
NPs on 3 consecutive days (100 mg/kg) in male FVB/N mice 
(~25 g) was used to investigate uptake in the small intestine 
and colon. The data showed that numbers of goblet cells in 
the colons of mice given DAPT/FA-PEG-PEI mesoporous 
silica NPs were significantly higher than DAPT alone or 
the empty NPs. Modified NPs were also able to increase 
the expression of MUC2 (gene encoding a member of the 
mucin protein family) in the colon. Interestingly, a similar 
trend of improvement and goblet-cell hyperplasia with 
PEG-PEI-coated NPs was seen in the small intestine. These 
data were further supported by an increased level of stool 
hydration in mice fed DAPT alone or DAPT/FA-PEG-PEI 
mesoporous silica NPs (indicative of Notch-inhibition-
induced cell switch from water-absorbing colonocytes to 
mucus-producing goblet cells). The authors concluded that 
the modified NPs were efficient carriers for drug delivery 
and targeted Notch inhibition following oral administration 
(particularly in the colon).62
Probucol is a routinely utilized drug with antioxidant and 
anti-inflammatory properties. It has also been reported that 
the drug can reduce the activity of MMP9 and decrease the 
expression of MCP1.63 These inflammatory factors are essen-
tial in certain features of cancer metastasis. In a recent study, 
a probucol nanoassembly was manufactured to increase the 
bioavailability of the drug (probucol is highly hydrophobic). 
The NP assembly (termed DNP) comprised probucol and 
Triton X-100 and was prepared via the self-assembly 
technique (~30 nm). The efficacy of the DNP formulation 
following oral administration was assessed in male Sprague 
Dawley rats (~200 g). The animals were administered 
200 mg/kg probucol in the DNP formulation or the free drug. 
Additionally, the distribution of fluorescently labeled NPs 
was quantified in the intestinal tract using an ex vivo imaging 
system. After oral administration, fluorescence intensity was 
highest in the duodenum, jejunum, and ileum. At each inves-
tigated time point, the probucol concentration in different 
intestinal segments was significantly higher for the DNP than 
the free prodrug suspension (4 hours post-DNP exposure, 
drug concentrations in the duodenum, jejunum, and ileum 
had increased by factors of 220, 195, and 233 respectively). 
Furthermore, TEM analysis showed DNP in endosomes or 
lysosomes of the enterocytes lining the intestinal villi. Next, 
oral pharmacokinetic data showed that the plasma concentra-
tion of probucol from DNP was much higher (~13-fold) than 
the free probucol suspension. In a subsequent experiment, 
the biodistribution of DNP in major organs was determined 
in female BALB/c mice (~20 g). DNP or the probucol sus-
pension was administered by oral gavage (200 mg/kg) and 
mice autopsied 4 hours postadministration. Ex vivo imag-
ing of the major organs showed that DNP was distributed 
mainly in the liver and lungs, with concentrations much 
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higher compared to the free probucol suspension. A series 
of in vitro experiments demonstrated that the invasion activ-
ity of 4T1 cells was inhibited by probucol and DNP, with 
inhibitory rates of 59% and 32%, respectively. Additionally, 
no cytotoxicity was detected in 4T1 cells following 24-hour 
treatment of DNP at concentrations of 0.004–4 µg/mL. 
Subsequently, the focus was placed on the establishment 
of the effectiveness of DNP in inhibition of lung metastasis 
in a rodent orthotopic breast cancer model. DNP treatment 
significantly improved the survival rate of mice relative to 
free probucol administration. Moreover, considerably more 
metastatic nodules were noted in the lungs of animals in 
the free probucol and control treatment groups, but rarely 
observed in the DNP-treated mice. The average number of 
visually detected metastatic nodules per lung was 12 in the 
control and free probucol groups, yet this was reduced to one 
in the DNP-treated animals. Finally, the in vivo toxic poten-
tial of the nanoassemblies was investigated in BALB/c mice 
administered orally (200 mg/kg per day) with the different 
formulations daily for 20 days. At this juncture, all major 
organs were removed for histological evaluation. The authors 
did not observe any significant histopathological alterations 
in DNP-treated animals compared to the controls. Therefore, 
it was concluded that the DNP presented good biocompat-
ibility at the doses and time points investigated. Overall, the 
study provided compelling evidence for the efficacy of the 
DNP formulation as a probucol-delivery platform and could 
be extremely valuable as a therapeutic strategy.64
DIM-D (1,1-bis[3′-indolyl]–1-[p-chlorophenyl] methane) 
is a novel semisynthetic derivative of diindolylmethane, a 
potent anticancer molecule that induces apoptosis, triggers 
cell-cycle arrest, and inhibits cell hyperproliferation in skin, 
bladder, and breast cancer cell lines. Notably, DIM-D obstructs 
ultraviolet B-induced generation of ROS. Further, the drug 
protects against oxidative damage evident by DNA damage, 
lipid peroxidation, and protein carbonylation, which usually 
precedes mutagenesis and photocarcinogenesis within ultra-
violet B-exposed skin cells. However, DIM derivatives are 
principally impermeable to biological membranes. In a recent 
study, the oral route of delivery was explored as a potential 
avenue for skin deposition of DIM-D following exposure of 
three lipid-based delivery systems. These consisted of: for-
mulation 1, DIM-D (10%), Captex oil (40%), Capmul MCM 
(20%), and Kolliphor HS15 (40%), ~40 nm; formulation 2, 
DIM-D (10%) diacylglycerol (Enova) oil (40%), Cremo-
phor RH40 (25%), Labrasol (15%), and vitamin E TPGS 
1000 (10%), ~84 nm; and formulation 3, DIM-D (0.1%), 
Compritol (3.75%), Miglyol (1.25%), Tween 80 (3.5%), and 
Pluronic F68 (1.5%), ~115 nm. In these experiments, male 
Sprague Dawley rats (~300 g) were administered doses of 
60 mg/kg orally of different formulations. Exposure to all 
formulations resulted in maximum blood concentrations of 
DIM-D at 2 hours postadministration, with levels highest 
for formulation 2 (6.2 µg/mL), which was significantly 
higher than formulation 1 (0.6 µg/mL) and formulation 
3 (0.3 µg/mL). Formulations 2 and 1 were 51.9- and 4.6-fold 
higher than the free drug solution, respectively. Next, the 
data demonstrated that formulation 1 resulted in the most 
significant deposition of DIM-D into the skin; however, all 
three formulations enhanced the amount of DIM-D depos-
ited in the skin. Finally, in vivo toxicity assessment of the 
different DIM-D formulations intended for prolonged usage 
was undertaken. In these experiments, SKH1 hairless mice 
were orally exposed at a dose of 100 mg/kg for 1 month, with 
hearts, lungs, kidneys, and livers harvested and subjected to 
histological analysis. Examination of each organ showed 
no histological changes between DIM-D-treated tissue and 
the negative control. In summary, the data from the study 
demonstrated effective enhanced oral bioavailability and skin 
deposition of DIM-D in the nanoformulations compared to 
the free drug solution.65
Oxaliplatin (Oxa) is a third-generation platinum antitu-
mor compound, which exerts its effects by interfering with 
DNA replication and transcription machinery through nuclear 
DNA-adduct formation. Clinically, Oxa is often utilized as 
a first-line chemotherapy strategy in combination with 5FU 
for treatment of advanced colorectal cancer.66 Presently, 
both drugs are administered by the intravenous route and 
exhibit poor oral bioavailability. However, a recent study 
aimed to develop an oral delivery system for Oxa and 5FU. 
This was achieved by constructing an ion-pairing complex 
of Oxa with a deoxycholic acid derivative (Nα-deoxycholyl-
l-lysyl-methylester [DCK], a permeation enhancer) before 
preparation of a multiple water-in-oil-in-water nanoemulsion 
incorporating Oxa-DCK and 5FU. The construct was charac-
terized and shown to be spherical and ,50 nm in size. In the 
first experiment, male Sprague Dawley rats (~200 g) were 
orally exposed to 10 mg/kg of the nanoemulsion or appropri-
ate controls. The authors showed that intestinal absorption 
of Oxa improved significantly after being incorporated in 
the nanoemulsion, resulting in a 1.66-fold increase in maxi-
mum plasma concentrations. Furthermore, oral absorption 
of Oxa was significantly enhanced by complex formation 
with DCK, and its maximum plasma concentrations were 
increased by 306% compared to the free drug. Next, CT26 
cells (mouse colon fibroblasts) were subcutaneously grafted 
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into the flanks of male BALB/c mice (~20 g). On day 14, 
when tumors became evident, the mice were orally exposed 
to the nanoemulsion formulation daily (10 mg/kg per 
animal) for 18 days. After the treatment, tumor mass in the 
nanoemulsion-treated group was reduced by 43% compared 
to the control animals. Finally, to determine the effect of oral 
combination treatment using the nanoemulsion (Oxa-DCK 
and 5FU)-delivery system on tumor-growth inhibition, 
proliferating-cell density and apoptosis in tissues were inves-
tigated. It was demonstrated that the nanoemulsion treatment 
resulted in a profound decrease in proliferating-cell density, 
as well as increased tumor apoptosis. The authors concluded 
that the oral administration of the nanoemulsion comprising 
Oxa-DCK and 5FU produced a synergistic effect on tumor-
growth inhibition due to improved oral bioavailability of 
Oxa and 5FU.66
In a recent study, a nanomicelle (corn oil, Labrasol, 
and Transcutol-P) drug-delivery carrier of tamoxifen and 
naringenin (flavonoid with anticancer and anti-inflammatory 
properties) was developed. Loaded micelles were charac-
terized and shown to be around 70 nm. Female Wistar rats 
(~250 g) were orally administered with the nanocarriers 
containing equivalent doses of tamoxifen at 10 mg/kg and 
naringenin 20 mg/kg body weight for up to 72 hours. In a 
concurrent lymphatic uptake study, the exposed animals were 
anesthetized before cannulation of the mesenteric lymph 
duct. Additionally, the antitumor potential of the formulation 
was assessed in a 7,12-dimethylbenz[a]-anthracene-induced 
female rat breast cancer model at a dose of 45 mg/kg for 
3 consecutive weeks at weekly intervals. The drug regimen 
was started after 10 weeks of 7,12-dimethylbenz[a]- 
anthracene exposure, followed by repeated oral dosing (once 
every 3 days) of the nanoemulsion. Furthermore, levels of 
ALT and AST in plasma, as well as hepatic glutathione 
and thiobarbituric acid-reactive substance alterations, were 
measured as a sign of drug-induced hepatotoxicity. The data 
showed that exposure to the micelles resulted in significant 
augmentation in drug maximum plasma concentrations 
after a single oral dose (11.5-fold increase). Additionally, 
the time that the drug was present at maximum concen-
tration in serum was reduced by 0.5-fold. Next, the data 
demonstrated the maximum lymphatic uptake for the NPs 
was 121.5 µg/mL and occurred in the first 3 hours, which 
was 3.8-fold higher compared to the free drug suspension. 
Examination of liver damage revealed the loaded nano-
emulsion to be atoxic at the doses administered. Finally, 
the in vivo anticancer activity of the nanoemulsion showed 
a reduction in tumor size of 85% compared to the free 
tamoxifen–naringenin suspension, which reduced tumor 
size by only 30%.67
20(S)-protopanaxadiol (PPD) is an aglycone metabolite 
that has exhibited powerful pleiotropic anticancer effects. 
The drug is currently undergoing phase I clinical trials in 
China.68 However, similar to several other anticancer agents, 
the compound has low oral absorption and is metabolized 
extensively in the liver. In a recent study, PPD was encap-
sulated in cubic NPs (~150 nm) prepared by fragmentation 
of glyceryl monooleate and poloxamer 407. The NPs were 
then linked to piperine (alkaloid with the potential to affect 
the bioavailability of other compounds) to generate a novel 
drug-delivery system. In these experiments, male Sprague 
Dawley rats (~200 g) were administered with oral doses 
equivalent to 2 mg/kg of PPD for up to 12 hours. The data 
demonstrated that the maximum concentration of free PPD 
after oral administration was 73.45 ng/ml and the time to 
maximum concentration was about 85 minutes. However, the 
maximum plasma concentration after oral administration of 
PPD cubosomes loaded with piperine was 142 ng/mL and the 
time to reach the maximum concentration was 110 minutes 
(oral bioavailability of 248% compared to the free drug). 
The data suggested that the increased bioavailability of 
PPD-cubosomes loaded with piperine was due to an increase 
in absorption and inhibition of PPD-NP metabolism, rather 
than improved release of PPD. Cubic NPs may prove to be 
a promising oral carrier for anticancer drugs with poor oral 
absorption and means of reducing hepatic metabolism.68
The MDM2 oncogene plays a critical role in the develop-
ment and progression of cancer through p53-dependent and 
p53-independent pathways.69 Ginseng is a natural product 
with a long history of chemopreventive use. The anticancer 
properties of ginseng have largely been attributed to the 
presence of saponins, which are termed “ginsenosides”. 
However, similar to other natural compounds, the therapeutic 
applications of these compounds are extremely limited, 
due to low aqueous solubility and instability under harsh 
GIT conditions, extensive metabolism, and rapid elimina-
tion. In a recent study, a novel ginsenoside, 25-OCH
3
-PPD 
(GS25; functions by inhibition of MDM2) isolated from 
Panax notoginseng was successfully encapsulated into 
PEG-PLGA NPs (~45 nm). The in vivo pharmacokinetics of 
GS25 and GS25 NPs were first assessed in male CD1 mice 
(~20 g). Additionally, PC3 human prostate cancer cells were 
subcutaneously injected into the left inguinal area of male 
CD1 mice. All animals were monitored for activity, physical 
condition, body weight, and tumor growth for 3 weeks. 
NPs were administered by oral gavage at a dose of 20 or 
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100 mg/kg/day 5 days a week for 4 weeks, while GS25 in 
PEG/ethanol/saline was administered at a similar dose for the 
same period. The data showed that compared to intravenous 
injection of 20 mg/kg GS25, oral administration of GS25 
(100 mg/kg) caused a very low peak value of drug concen-
tration (0.9 µg/mL), due to low bioavailability (~15%). The 
NP encapsulation of GS25 resulted in dramatically altered 
plasma concentration times (20 and 100 mg/kg oral doses of 
GS25 NPs increased to 21.4 and 93.1 h⋅µg/mL). Compared 
to oral administration of GS25 at a dose of 100 mg/kg, 
drug concentrations of 20 and 100 mg/kg GS25 NPs were 
three- and ninefold higher, respectively. On a similar theme, 
compared to free GS25, GS25 NP half-life was extended 
to .7 hours. Furthermore, tissue biokinetic data showed 
that drug accumulation was increased by the nanodelivery 
system in the liver, lungs, kidneys, spleen, heart, brain, and 
pancreas. To investigate the effects of NP encapsulation on 
tumor uptake further, pharmacokinetic studies of GS25 and 
NP formulation were performed in nude mice bearing PC3 
xenograft tumors. Consistently with the pharmacokinetic 
profiles in CD1 mice, the encapsulation of GS25 increased 
plasma drug concentrations. More importantly, there was a 
substantial increase in the tumor uptake of the NPs compared 
to GS25 alone. To determine the optimal therapeutic doses 
of GS25 and GS25 NPs, initial maximum-tolerated-dose 
studies were performed in CD1 mice. The data showed no 
toxicity to the mice at a dose of up to 400 mg/kg. Further, 
histological examination of various tissue samples from 
treated animals showed no pathological alterations. Next, the 
anticancer efficacy of GS25 and GS25 NPs was evaluated 
using the PC3 xenograft model of human prostate cancer. 
The authors demonstrated that 100 mg/kg GS25 had mod-
erate effects on tumor growth (4-week oral treatment led to 
approximately 41% inhibition of PC3 tumor growth). How-
ever, treatment for the same period using 20 and 100 mg/kg 
GS25 NPs inhibited the growth of PC3 xenograft tumors by 
approximately 75% and 87% respectively. Finally, expres-
sion levels of MDM2 and other apoptosis-related proteins 
were examined in vivo. It was noted that NP encapsulation 
enhanced the effects of GS25 on the expression of MDM2, 
poly-ADP-ribose polymerase, and Bax. In summary, the 
study provided compelling evidence for an efficient oral 
nanodelivery system as an MDM2 inhibitor with potential 
practical applications in cancer therapy.70
Harmine is a β-carboline compound that has been attrib-
uted with antitumor properties. However, the compound 
has very poor oral bioavailability. In a strategy to improve 
the suitability of the compound in medical applications, 
the drug was encapsulated in N-trimethyl CS-coated lipo-
somes (soybean phosphatidylcholine–cholesterol 20:5 
w:w; ~170 nm). In this study, Sprague Dawley rats (~250 g) 
were exposed to the liposomes at doses of 60 mg/kg. The 
data showed that the elimination rate of free suspension of 
the compound was faster than that of liposome formulation 
(by up to 4 hours). In addition, the bioavailability of harmine 
through oral administration was enhanced by 60% in the 
nanoformulation compared to the free drug. One possible 
explanation for enhancement of the bioavailability of encap-
sulated drugs is the opening of tight junctions in intestinal 
epithelial cells caused by the N-trimethyl CS coating.71
Infectious and parasitic diseases
Luteolin is believed to have antimicrobial, anti-inflammatory 
and antimutagenic properties. However, despite its benefi-
cial biological activities, the flavone has low oral bioavail-
ability due to very poor water solubility. In a recent study, 
glycerol monostearate and Tween 80 luteolin-loaded NPs 
(~50–120 nm) were manufactured to attempt to overcome 
this issue. Male Sprague Dawley rats were orally exposed 
to the NPs at a dose of 20 mg/kg. The data demonstrated that 
the drug encapsulated in the NP formulation had significantly 
higher solubility and bioavailability in plasma compared to 
the native drug suspensions. Moreover, the time taken for 
clearance of drug incorporated within the NPs was signifi-
cantly decreased.72
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
among the most commonly prescribed globally for their 
antipyretic, analgesic, and anti-inflammatory effects. How-
ever, it has been reported that the use of NSAIDs may cause 
severe adverse effects, including the development of ulcers, 
bleeding, and perforation in the GIT. Based on the principle 
that antioxidant compounds and free-radical scavengers heal 
NSAID-induced inflammation, in a recent study a redox NP 
(RNPO) formulation with the ROS-scavenging potential of 
nitroxide radicals was developed. The RNPO was composed 
of a core micelle (~40 nm), prepared by the self-assembly of 
methoxy-PEG-poly[4-(2,2,6,6-tetramethylpiperidine-1-oxyl)
oxymethylstyrene] and an amphiphilic block polymer pos-
sessing nitroxide radicals as side chains of the hydrophobic 
segment. The antioxidant potential of the NPs was assessed 
in a male ICR (~30 g) mice model in which the animals were 
pretreated (oral gavage) with 13.34 mg/mL of NPs 1 hour 
before induction of small-intestine inflammation following 
the administration of indomethacin (Ind). The data demon-
strated significant histological damage in both the jejunum 
and ileum of mice treated with Ind, manifested predominantly 
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as focal and upper villous necrosis. However, histology of 
small intestines from RNPO-treated mice showed almost no 
damage and appeared similar to the control mice. Unsurpris-
ingly MPO activity was significantly increased in the small 
intestines of Ind-treated mice, suggesting increased neutro-
phil invasion in the ileum region. MPO levels decreased 
significantly in the jejuna and the ilea of mice pretreated 
with RNPO. Overall, the authors demonstrated that RNPO 
pretreatment efficiently scavenged superoxide anions in an 
Ind-induced small-intestine-inflammation model. As such, 
it was suggested that oral administration of RNPO prior to 
oral exposure to NSAIDs might be beneficial in the treat-
ment of small-intestine injury in patients on regular NSAID 
medication.73
AIDS is traditionally treated with nucleoside reverse-
transcriptase inhibitors (NRTIs); however, this antiretroviral 
therapy has limited bioavailability and biodistribution 
(inherent hydrophilic nature, hence their effectiveness in 
accessing virus sanctuaries is limited).74 To overcome these 
limitations, in a 2013 study NRTIs were loaded into lipo-
some nanocarriers to modulate drug biodistribution. The 
authors investigated the antiviral efficacy of the nucleoside 
analogs of dideoxycytidine and didanosine in nanoassemblies 
(1-hydroxybenzotriazole hydrate, O-(7-azabenzotriazol-1-
yl)-N,N,N,N′-tetramethyluronium hexafluoroborate, dide-
oxycytidine, and diisopropylethylamine; 100–300 nm) on 
HIV. These nanoassemblies were further modulated with 
PEG coupled to either cholesterol or squalene. Wistar rats 
(~200 g) were treated with the different formulations at a dose 
of 45 mg/kg via oral gavage. The nanoformulation showed 
greater absorption and higher diffusion into the liver, spleen, 
bone marrow, thymus, and brain (all tissue associated with 
HIV infection). Furthermore, nanoformulation treatment 
of infected blood mononuclear cells in vitro resulted in 
enhanced antiviral efficacy compared to the parent NRTIs, 
with a two- to threefold decrease in 50% effective dose and 
a near doubling in drug-selectivity-index score.74
Combination pharmacotherapy is commonly adminis-
tered for treatment of AIDS. However, it is often difficult 
simultaneously to deliver all active components of the drugs 
to targeted cells and maintain an effective concentration using 
current delivery methods.75 Nanocarriers could potentially 
entrap different types of drugs and deliver the pharmaceu-
tics to desired destinations. In a recent study, this strategy 
was utilized for highly active antiretroviral therapy via the 
oral route. A bolaamphiphilic prodrug termed ZPDD was 
prepared via the combination of azidothymidine (Azt) and 
didanosine (Ddi). The nanoscale self-assemblies (~174 nm) 
were then used to target macrophages, both in vitro and 
in vivo. Male Kunming mice (~25 g) were exposed to ZPDD 
self-assemblies at 100 mg/kg per animal. Furthermore, the 
anti-HIV action of ZPDD self-assemblies was explored in 
HIV1-infected MT4 (human T-cell leukemia-derived lym-
phocyte) cells. It was noted that ZPDD had high antiviral 
activity with EC
50
 of 5 nM, equal to the EC
50
 of Azt. Oral 
administration of ZPDD self-assemblies resulted in sig-
nificant dose (up to 20 nmol/g) accumulation in the spleen, 
lymph nodes, thymus, liver, and lungs, with high macrophage 
accumulation. Interestingly, the molar concentration of Azt 
was much higher than that of ZPDD in the targeted tissue. 
The authors attributed these findings to the rapid degradation 
of the ZPDD self-assemblies. Finally, the study demonstrated 
that the bioavailability of ZPDD was 31% in comparison 
to the same dose administered via the intravenous route. 
The relatively low oral bioavailability may be related to the 
unstable properties of the assemblies in the stomach, enzyme 
damage, or insufficient absorption into the bloodstream. 
Overall, the data demonstrated that the self-assembly could 
deliver two types of drugs simultaneously to targeted tissue 
at a relatively high dose. However, it had poor bioavailability 
following oral exposure.75
Efavirenz (Efv) is considered first-line therapy for new 
cases of HIV. However, the drug is expensive, and this is 
a genuine issue in developing countries. In a very interest-
ing recent study, emulsion-templated freeze-drying was 
utilized for the manufacture of solid Efv NPs with the aim 
of the development of a cheaper, more effective oral anti-
HIV formulation. After an initial screening of 49 different 
stabilizers, one formulation was identified as the most effec-
tive in terms of low cytotoxicity (epithelial colorectal cells) 
and greatest cellular permeability (70:20:10 weight ratio 
of Efv, PVA, and α-tocopherol–PEG succinate). Particles 
were characterized extensively, and confirmed to be around 
300 nm in size. In these experiments, male Wistar rats were 
exposed to 10 mg/kg of the traditional or nanoformulated 
Efv, with blood samples collected at 15, 30, 45, 60, 120, 180, 
240, and 300 minutes postexposure. The data demonstrated 
that at an equivalent dose, significantly higher plasma maxi-
mum concentration was achieved for the nanoformulation 
compared to the traditional medicine: maximum concentra-
tion (478 vs 126 ng/L) and minimum concentration (379 vs 
80 ng/L). In summary, the data showed that the identified 
nanoformulation might prove to be a viable option for the 
scalable manufacture of cheaper Efv.76
One of the main impediments to the effective treatment 
of HIV is the numerous viral sanctuaries, ie, lymph nodes 
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or the intestine, which are often inaccessible to traditional 
anti-HIV compounds (ie, the prodrug Ddi). In an attempt to 
address this issue in a 2011 study, a multilamellar dipalmi-
toylphosphatidylcholine vesicles were utilized to encapsulate 
Ddi (~100 nm). For long-term storage and subsequent experi-
ments, the vesicles were freeze-dried. First, phytohemag-
glutinin P-activated peripheral blood mononuclear cells were 
treated with increasing concentrations of loaded vesicles. 
Following a 1-hour incubation, cells were infected with an 
HIV1 LAI strain. Viral replication was measured by quantify-
ing reverse-transcriptase activity. In parallel, the cytotoxicity 
of the compounds was evaluated in uninfected phytohemag-
glutinin P-activated peripheral blood mononuclear cells. The 
data demonstrated that the vesicles were effective against the 
HIV1 LAI with an ED
50
 of 9.9 µM and had relatively low 
cytotoxicity (LD
50
 .100 µM) compared to the unencapsu-
lated drug with ED
50
 of 1.2 µM and LD
50
 of 40 µM. Next, 
Wistar rats (~200 g) were exposed to 45 mg Ddi/kg via the 
oral route. Pharmacokinetic and biodistribution data showed 
that at 4 and 8 hours postadministration, drug plasma concen-
trations were six- and fivefold higher, respectively, for the 
nanoformulation compared to the free molecule. The drug-
loaded liposomes presented a higher terminal elimination 
half-life (2.37 hours) than the free drug (0.76 hours). Next, 
evaluation of drug biodistribution at 24 hours postexposure 
with radiolabeled loaded liposomes revealed a higher distribu-
tion of the liposomal formulation (most visible in the intestine, 
spleen, and testicles). Moreover, radioactivity recovered in 
plasma was fourfold higher after liposomal administration 
than the free drug. Finally, urinary excretion of the liposome 
drug-delivery system was increased compared to that of free 
drug whereas the feces excretion was very similar for both 
treatments. In conclusion, the data showed preservation of 
Ddi encapsulated in the liposomes with enhanced antiviral 
activity, blood half-life, and intestinal accumulation.77
As mentioned previously, the therapeutic efficacy of a 
drug administered by the oral route strongly depends on the 
administered dose, GIT absorption, and its bioavailability. 
To improve the oral bioavailability of Efv in another recent 
study, the drug was encapsulated within poly-ε-caprolactone 
PVA NPs (~250 nm). Oral pharmacokinetics of Efv were 
assessed in male Wistar rats (~300 g). The animals were 
administered the drug at equivalent doses of 20 mg Efv/kg via 
oral gavage. The authors observed that the encapsulation of 
Efv in the manufactured NP construct significantly increased 
the oral bioavailability of the drug (4.8-fold) when compared 
with pure Efv NPs (prepared by employing the same meth-
odology without the addition of the poly-ε-caprolactone).78
Primaquine (Pq) is a widely used antimalarial drug. 
To date, it is the only available drug for combating the 
relapsing form of malaria. However, the drug has serious 
side effects, including nausea, vomiting, methemoglobin-
emia, leukopenia, leukocytosis, and abdominal cramps.79 In a 
recent set of trials, Pq-loaded positively charged PVA SLNs 
(Pq-SLNs; 236 nm) were utilized to enhance drug efficacy 
and half-life with the aim of reducing toxicity and better 
patient compliance. The ζ-potential of the SLNs changed 
from -6.54 mV to 23 mV by binding positively charged 
CS as a surface modifier. To investigate the efficacy of the 
drug formulations, Swiss albino mice (~25 g) were infected 
with blood containing parasitized Plasmodium berghei 
ANKA. Following 2 hours’ incubation, the test animals were 
orally exposed with two doses of either Pq-SLNs or free Pq 
(2 or 5 mg/kg/day). Drug administration was repeated at 
24, 48, and 72 hours postinfection. The authors noted that 
treatment with Pq-SLNs at a dose of 2 mg/kg/day resulted 
in chemosuppression of 94% in comparison to 72% in mice 
treated with free Pq at a similar dose. Additionally, it was 
observed that formulation of Pq in the nanoemulsion had 
effective antimalarial activity against P. berghei at a 25% 
lower dose compared with the conventional oral formula-
tion. In summary, the study demonstrated that the SLNs 
were small enough to allow direct absorption into the GIT. 
This, coupled with a positive surface charge, might allow for 
high hepatic absorption. The drug is highly effective against 
hypnozoites (liver stage of all malaria species), which would 
explain why the formulation was highly efficacious, even at 
a reduced dosage.79
Amphotericin B (AmB) is one of the most effective anti-
fungal drugs available for the treatment of systemic fungal 
infections, such as candidiasis or aspergillosis. Furthermore, 
it is prescribed for the treatment of visceral leishmaniasis. 
The traditional intravenous administration of AmB in the 
current marketed formulations results in high drug levels 
in target organs, but is also associated with significant 
accumulation in the kidneys, which is highly problematic, 
as the drug is a known nephrotoxin. In a recent study, the 
effects of administration of AmB in an N-palmitoyl-N-
monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycol CS 
(GCPq) self-assembling NP system via the oral route (as a 
means of protecting the drug from gastric degradation and 
selective transportation to target organs, hence diminishing 
kidney exposure) was investigated. The AmB-GCPq resulted 
in the solubilization of AmB crystals and the formation of 
highly stable NPs (35–200 nm). First, the biokinetics of the 
drug were investigated in a male CD1 mouse model (~30 g). 
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The authors showed that for all formulations (traditional and 
GCPq), AmB plasma concentrations increased slowly and 
were sustained for 8 hours postadministration. The drug was 
mainly tissue-bound and accumulated in the liver, spleen, 
and lungs. However, AmB-GCPq administration resulted 
in higher plasma levels when compared to AmB in dextrose 
(oral bioavailability of AmB-GCPq NPs was 25%). Further-
more, significantly higher levels of AmB were found in the 
livers of AmB-GCPq-exposed animals. Next, the efficacy of 
oral administration of the GCPq NPs was investigated in three 
separate disease states (visceral leishmaniasis, candidiasis, 
and aspergillosis) using standard models of the disease in 
different murine models. For all experiments, animals were 
dosed with 1 or 5 mg/kg of different drug formulations. It was 
noted that the AmB-GCPq NPs targeted organs of pathology, 
resulting in effective treatment in preclinical disease models 
(particularly evident for aspergillosis and systemic candidi-
asis). The study provided preliminary evidence of the effec-
tiveness of the use of particular NPs for specific targeting of 
drugs to key organs via the oral route.80
Triptolide (Tp) is a compound extract derived from 
traditional Chinese medicine. Tp has been documented to 
possess a wide array of unique bioactive properties, ie, anti-
inflammatory, anticystogenesis, and anticancer activities.81 
However, the clinical use of Tp has been heavily hampered, 
due to its high toxicity to the hepatic, renal, digestive, and 
reproductive systems. The unique pharmacokinetics of Tp 
signify that it gains fast access to blood circulation and is 
rapidly metabolized with extensive tissue distribution, which 
all contribute to its toxic nature. In a 2014 study, two nano-
scale delivery systems were utilized to extend the delivery 
time for the chemical and decrease the fluctuations of Tp in 
plasma with the aim of potentially reducing the adverse side 
effects associated with traditional oral delivery formats. The 
authors used Cremophor RH40, Lipoid E80, and Transcutol 
HP to formulate a nanostructured lipid carrier composed 
of solid and liquid lipids termed NLC (~230 nm) and an 
entire SLN (~180 nm). Firstly, the pharmacokinetics of the 
loaded carriers were examined in male Sprague Dawley rats 
(~300 g). The rodents were orally administered the Tp-NLCs, 
Tp-SLNs, or free Tp at a dose of 544 µg per animal. Time to 
maximum concentration and half-life of free Tp in plasma 
were calculated as 12 and 42 minutes, respectively. However, 
maximum concentration of Tp was delayed to 43 minutes 
and 27 minutes for Tp-NLCs and Tp-SLNs, respectively. 
The half-life was very similar for the two nanoformulations, 
calculated at around 90 minutes. In subsequent subacute-
toxicity studies, rats were exposed to free Tp and the two 
carrier systems at two doses (500 and 650 µg/kg). The drugs 
were administered daily by oral route for 28 days. Firstly, 
statistically significant decreases in weight gains were noted 
with the high doses of free Tp and Tp-SLN in the second 
week. This was appraised as GIT toxicity of Tp. After the last 
measurement, the decrease in weight gains in the Tp-NLC 
group was significant compared to the free Tp group and 
was considerably smaller than that of the Tp-SLN group 
at the high dose utilized. Next, levels of ALT and AST in 
plasma were measured as a sign of liver damage and found 
to be significantly elevated following exposure to Tp. Expo-
sure to Tp-NLC and Tp-SLN showed no marked elevation 
at 500 µg/kg. However, AST and ALT levels were both 
increased in animals exposed to 650 µg/kg Tp-SLNs and 
were comparable to the Tp controls. In contrast, oral exposure 
to 650 µg/kg Tp-NLC was not associated with liver damage 
measured by plasma AST and ALT alterations. Increased 
serum creatinine and blood urea nitrogen concentrations in 
the blood can be indicative of renal dysfunction. At the high 
dose of 650 µg/kg, both Tp- and Tp-SLN-exposed animals 
had higher creatinine and blood urea nitrogen than the control 
group, while Tp-NLC exposure showed no significant renal 
toxicity. Malondialdehyde as a by-product of lipid peroxida-
tion was demonstrated to be elevated following exposure to 
the free Tp and the Tp-NLC formulation at the higher dose 
utilized in these experiments (although the reliability of the 
assay is questionable). Finally, histopathological changes 
in the liver, spleen, and kidneys were observed in animals 
exposed to high doses of Tp and Tp-SLNs. This pathology 
was manifested as fatty degeneration in hepatocytes, dead 
cells phagocytosed in the spleen, macrophages in the white 
pulp, and clear proximal tubular dilations in the kidneys. 
However, in Tp-NLC-exposed rats, no apparent changes 
were found. It is important to state that the histopathology 
was not quantified in this study and the observations only 
descriptive in nature.81
Andrographolide (Adg) is the main active ingredient of 
the herbaceous plant Andrographis paniculata, commonly 
used in Chinese medicine and with acknowledged anti-
bacterial and anti-inflammatory properties. Unfortunately, 
the clinical use of Adg is limited, due to its extremely poor 
solubility following oral administration. In an attempt to 
increase the bioavailability of the drug in a recent set of trials, 
an Adg nanosuspension (Adg-NS) was prepared via wet-
media milling and freeze-drying d-α-tocopheryl PEG1,000 
succinate and sodium lauryl sulfate. The prepared NPs were 
shown to be around 215 nm in size. Pharmacokinetics analysis 
of the NS in male Sprague Dawley rats (~250 g) following 
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oral exposure of 40 mg/kg Adg resulted in significantly higher 
mean plasma concentrations compared to commercially avail-
able dripping pills. Next, a carrageenan-induced paw-edema 
model was utilized in a male Kunming mouse model (~25 g) 
to investigate the anti-inflammatory potential of the NS. The 
animals were treated once daily by oral gavage with aspirin 
(150 mg/kg), coarse Adg powder, Adg dripping pills, or the 
freeze-dried Adg-NS (all at 40 mg/kg) for 4 days. On the 
fourth day, 30 minutes after the last administration, 1% car-
rageenan was injected into the right hind paws of the mice 
and paw volume measured over time. The authors noted that 
the NPs were extremely effective in reducing paw swelling 
(swelling reduced from 30 minutes postexposure, 52.5% 
decreased swelling after 1 hour) and comparable to aspirin. 
Additionally, a significant reduction in plasma levels of nitric 
oxide, IL1, and TNFα levels and an increase in superoxide 
dismutase activity were observed in the sera of mice treated 
with the Adg-NS. Overall, the data from the study seemed 
to indicate that Adg incorporated in the nanoformulation has 
enhanced oral bioavailability and biological efficacy.82
Baicalein (Bcl) is a flavonoid sourced from Scutellaria 
baicalensis. The metabolite has been reported to have 
anticancer, antioxidant, antiviral, and anti-inflammatory 
properties. However, poor intestinal solubility and oral bio-
availability have dramatically limited its clinical efficacy. 
Therefore, nanoemulsions composed of hemp oil, PEG 
monooleate, and sodium oleate (~90 nm) were developed 
to improve the intestinal stability and permeability of Bcl. 
In these experiments, Sprague Dawley rats (~250 g) were 
administered the nanoemulsion at a dose of 25 mg/kg via oral 
gavage for up to 12 hours. The authors demonstrated that the 
Bcl NPs yielded higher blood Bcl concentrations at all time 
points. The maximum plasma concentration was 42 µg/mL, 
with oral bioavailability of nanoemulsions calculated to be 
increased by 523% and 242% relative to the free suspensions 
and conventional emulsions, respectively.83
Miltefosine has shown potential to be effective against 
certain developmental phases of Schistosoma mansoni. In a 
recent study, the effectiveness of miltefosine as a potential 
antischistosomal drug was investigated in a selection of 
lipid nanocapsules composed of Solutol and Labrafac. 
This was followed by coating of the liposomes with either 
dicetyl phosphate (anionic), hexadecyltrimethylammo-
nium bromide (cationic), oleic acid, or CS (~50 nm). In 
these experiments, S. mansoni-infected male Swiss albino 
mice were exposed to a single 20 mg/kg oral dose of 
miltefosine, either as an aqueous solution or the same con-
centration encapsulated in the lipid nanocapsules, with the 
animals killed 7 days posttreatment. Administration of the 
miltefosine-encapsulated formulations reduced the mean 
worm burden to different extents, with the hexadecyltrim-
ethylammonium bromide (42%) and the oleic acid (88%) 
being the most effective. Additionally, lipid nanocapsule 
treatment was associated with ameliorated liver pathology 
and extensive damage to the worm tegument (outer body of 
the parasite). The data seem to suggest that the miltefosine 
nanocapsules can enhance therapy of S. mansoni, even after 
a single oral dose.84
In a 2013 study, vaccination with encapsulated outer-
membrane vesicles (OMVs) (naturally released from the 
cell) of Shigella flexneri was utilized as a protection strat-
egy to protect mice against an experimental infection with 
shigellosis. In these experiments, BALB/c mice (~20 g) were 
immunized with either free OMVs or OMVs encapsulated in 
polyanhydride NPs (~150 nm) via the oral route at doses of 
50 or 100 µg OMVs. On week 8, the animals were infected 
intranasally with a lethal dose of the bacteria. The authors 
showed that all immunized animals remained in good health 
compared to controls (exhibiting no respiratory difficulties or 
changes in body temperature). Furthermore, a clear adjuvant 
effect of the encapsulation of OMVs into NPs was detected 
(IgG
1
 levels). Interestingly and importantly, following chal-
lenge with the lethal dose of S. flexneri, oral immunization 
with free OMVs or NPs provided high levels of protection 
(80% and 100%).85
Diseases of the nervous system
Levodopa (l-dopa) has been the standard drug for treatment 
of Parkinson’s disease. It is a precursor to the neurotransmit-
ters dopamine, norepinephrine, and epinepherine. l-dopa can 
cross the blood–brain barrier (BBB), whereas dopamine is 
unable to do so.86 Therefore, l-dopa can be used to increase 
effective dopamine concentrations in the treatment of 
Parkinson’s disease. The utilization of nanocarrier systems 
would allow for delivery of drugs across the intact BBB for 
this purpose. In a recent study, the toxicity assessment of a 
layered double hydroxide (LDH) l-dopa-delivery system 
with controllable ion-exchange capacity and pH-dependent 
solubility was undertaken. The delivery system was devel-
oped with 16% loading of l-dopa into a zinc–aluminum 
layered hydroxide nanocomposite. The synthesized LDH 
construct demonstrated pH-dependent sustained release with 
improved thermal stability. In these trials, Sprague Dawley 
rats (~250 g) were exposed to the nanocomposites once daily 
for 28 days at doses of 5 or 500 mg/kg body weight via the 
oral route. First, animals treated with zinc–aluminum LDH 
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intercalated with l-dopa over 28 days showed no signs of 
discomfort or mortality. Food and water intake was unaf-
fected during the study period. Additionally, no signs of 
vomiting, diarrhea, paralysis, convulsion, irritation, bleeding, 
or breathing difficulties were observed. However, analysis of 
the biochemical parameters showed elevated levels of AST 
in nanocomposite-treated animals in comparison to the con-
trols, indicative of hepatotoxicity following exposure to the 
zinc–aluminum LDH intercalated with l-dopa at the higher 
dose. Next, urea, electrolyte, and creatinine levels were 
analyzed after the 28-day oral dosing of the rats. The data 
demonstrated that all electrolyte and urea levels were within 
the same range as the control groups. Finally, histological 
examination of the liver showed well-preserved hepatocyte 
morphology: a well-maintained lobular array around the 
central vein, radiating sinusoids, and normal portal triads. It is 
very possible that mild liver injury manifested as elevated 
ALT levels occurred without any clinical symptoms. How-
ever, small inflammatory changes were noted in kidneys 
of treated animals, notably as leukocyte infiltrations in the 
tissue. Overall, the data suggest that oral administration of 
the LDH construct at doses up to 500 mg/kg resulted in only 
mild clinical toxicity. The data clearly signified the necessity 
for additional and more detailed examination of the acute 
hepatic and renal adverse effects after oral dosing with the 
nanocomposite.87
It is understood that excessively generated reactive 
oxygen species are associated with age-related neurodegen-
erative disease. In a recent study, the scavenging potential 
of reactive oxygen species in the brain was investigated 
following oral administration of RNPO (40 nm), prepared 
by self-assembly of redox polymers possessing antioxidant 
nitroxide radicals in a male senescence-accelerated-prone 
mouse model. In these experiments, NPs were delivered via 
the oral route (300 mg/kg) for 30 days. The data demonstrated 
that levels of oxidative stress in the brain of exposed mice 
were remarkably reduced, which in turn resulted in the ame-
lioration of cognitive impairment with increased numbers of 
surviving neurons. In order to assess the safety of the redox 
polymer nanotherapeutics, body weight, vital organ weight, 
blood pressure, and histological features of vital organs were 
measured. The authors observed no significant differences 
in body weight or histopathological alterations in major 
organs (liver, spleen, kidney, lung, testicles, or heart) of 
NP-exposed animals.88
There is a degree of uncertainty in regard to the effective-
ness of the colloidal systems designed for central nervous 
system targeting (ability to bypass the BBB) following 
oral exposure. To address this issue, two murine models 
(male albino Wistar Hannover rats [~200 g] and C57BL/6 
mice [~25 g]) were exposed to specifically manufactured 
fluorescently labeled-PLGA NPs (termed g7-NPs). The NPs 
were characterized and demonstrated to be 140–200 nm in 
size. Following an acclimatization period, the animals were 
orally exposed (rats, 10 mg/animal; mice, 3 mg/animal) to 
the NPs for 180 minutes. The authors reported a clear and 
preferential localization of NPs around the neuronal nuclei, 
which showed the ability of g7-NPs to cross the BBB. It is 
important to note that the principal body of data generated in 
this study was qualitative in nature with no physiologically 
relevant large doses. Therefore, further work is required to 
corroborate the findings within this investigation.89
Diseases of musculoskeletal and 
connective tissue
Arthritis is a chronic inflammatory disease involving irre-
versible damage to the joints of the body. Currently, a broad 
variety of therapeutics are available for the treatment of 
arthritis, including the use of analgesics, glucocorticoid, and 
NSAIDs. Unfortunately, it is challenging to create highly 
efficient oral delivery systems with site-specific therapeutic 
release capacity. To address some of these challenges, male 
Sprague Dawley rats (~250 g) were orally administered 
(2.5, 5, and 10 mg/kg) Ind-containing nanocarriers (assem-
bly of β-cyclodextrin-conjugated PEI; 205 nm). The NPs 
exhibited a spherical shape and were positively charged. 
The data demonstrated that the Ind plasma concentration 
in the nanomedicine group was significantly higher than 
that of the traditional medicine-administered group. Tissue-
distribution studies showed high levels of Ind in the heart, 
spleen, kidney, and lungs. Importantly, treatment with Ind 
NPs at 5 and 10 mg/kg almost completely inhibited carra-
geenan-induced acute inflammation and complete Freund’s 
adjuvant-induced arthritis (enhanced therapeutic activity 
of the NP, even at a low dosage). The authors showed the 
bioavailability of Ind can be dramatically enhanced by utiliza-
tion of the nanoformulation in comparison to commercially 
available Ind tablets. It was postulated that the formulation 
might serve as a highly efficient and effective delivery plat-
form for the oral delivery of water-insoluble therapeutics in 
clinical settings.90
Bisphosphonates that inhibit osteoclast resorption are 
used widely in the treatment and prevention of osteoporosis. 
In general, bisphosphonates are eliminated by urinary 
excretion and have very low oral bioavailability.91 Oral 
administration of this class of drugs is associated with a 
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range of undesirable side effects, including diarrhea, nausea, 
vomiting, esophageal inflammation, and the development of 
ulcers. One such drug, risedronate, is poorly absorbed and 
associated with a range of toxic effects when taken orally. 
It is understood that oral risedronate can form an insoluble 
complex with calcium and magnesium in food. Therefore, 
there is a strong need to develop more efficient drug-delivery 
systems for risedronate with less propensity to cause esopha-
geal irritation and better bioavailability. In a 2014 study, a 
CS-coated liposome was developed to improve the intestinal 
drug absorption of the drug. The liposomes were prepared 
via the freeze-drying method using the combination of the 
lipids 1,2-distearoryl-sn-glycero-3-phosphocholine and 
distearoryl-sn-glycero-3-(phospho-rac-[1-glycerol]), with 
subsequent coating of the liposomes with CS (~950 nm). 
In these experiments, male Sprague Dawley rats weighing 
about 250 g were orally exposed to the liposomes at a dose 
equivalent to 5 mg/kg risedronate. The authors noted that 
the CS-coated liposome formulation increased the amount 
of drug excreted in the urine threefold in rats compared with 
the free drug formulation. The use of CS-coated liposomes 
may prevent or considerably reduce the interaction with food, 
thus reducing the esophageal irritation associated with the 
traditional formulations of the drug. The findings from this 
study suggested that CS-coated liposomes could improve the 
oral bioavailability of risedronate.93
Parathyroid hormone (PTH) is one of the major hormones 
regulating calcium-ion concentrations in the blood.93 Ana-
bolic functions are stimulated by intermittent exposure to 
PTH, resulting in differentiation and proliferation or reduced 
apoptosis of osteoblasts.94 Furthermore, catabolic functions 
are stimulated by continuous PTH exposure and associated 
with increased receptor activator of NFκB-ligand expression 
and inhibition of osteoprotegerin expression.94 Teriparatide, 
a recombinant human PTH (1–34), is currently used clini-
cally to treat osteoporosis in postmenopausal women and 
hypogonadal osteoporosis in men. However, the drug is 
currently administered once daily via subcutaneous injec-
tion and is often associated with poor patient compliance. 
In an attempt to improve patient acquiescence, an enteric 
microcapsule containing an ionic nanocomplex of PTH 
(1–34) and lysine-linked deoxycholic acid of the drug was 
manufactured (~35 nm). In these experiments, bilateral 
ovariectomy was performed in female Sprague Dawley 
rats (~200 g) to induce osteoporosis. The antiosteoporotic 
effects of the orally administered nanocomplex were evalu-
ated in these animals following exposure of the carriers at 
doses of 50 µg/kg. Twelve weeks after the treatments, the 
left and right tibiae were removed. The data showed that the 
rats treated with oral PTH–lysine-linked deoxycholic acid-
loaded enteric microcapsules had increased bone-mineral 
density (159%), bone-volume fraction (175%), and trabecular 
numbers (174%) compared with the controls. It appears that 
the novel nanocomplex oral delivery system described could 
be a promising treatment modality for osteoporosis due to 
enhanced osteogenesis and trabecular connectivity.94
Other or unspecified diseases
In order to overcome the challenge of drug insolubility, 
C57/BL6 mice were orally exposed to solidified (lyo-
philized) monomethoxy-PEG-PLA micelles encapsulating 
the hydrophobic molecule 6-coumarin (~20 nm). The 
micelles were administered at 30 mg/mL for 2 hours. TEM 
analysis demonstrated that labeled micelles were present 
in significant numbers in the small intestines of exposed 
animals. Additionally, in a concurrent in vitro experiment, 
endocytosis of the micelles by Caco2 cells was demonstrated 
to be clathrin-mediated and both energy- and temperature-
dependent, which is indicative of specific receptor binding. 
The authors summarized that the particular micelles used 
in this study could be beneficial in oral delivery of poorly 
soluble small molecules.95
For any oral medicine to be effective, it must negotiate 
and bypass multiple physiological barriers, including the 
avoidance of enzymatic degradation in the harsh gastric 
environment or overcoming the generally poor permeability 
across the intestinal epithelium. Additionally, the tendency 
for immunotolerance being favored in the gut means that 
effective oral immunization in general is very challenging. 
To address these limitations in a topical study, tetanus toxoid 
encapsulated glucomannan-O-carboxymethyl–distearyl 
phosphatidylethanolamine conjugate bilosomes (a colloidal 
delivery system incorporating bile salts into the vesicular 
lipid bilayer membrane; ~150 nm) were manufactured. The 
bilosomes were prepared by a combination of sodium deoxy-
cholate (bile acid), Span 80 (surfactant), and cholesterol 
(0.1:2:1 ratio). Male BALB/c mice were immunized with 
five flocculation units of tetanus toxoid via oral gavage. The 
animals further received a second immunization on day 22. 
At the end of day 35, the glucomannan bilosomes elicited 
a significantly higher systemic immunoresponse (measured 
by serum IgG levels) compared to all controls. Additionally, 
the bilosomes were capable of inducing a strong mucosal 
immunoresponse (soluble IgA titer in salivary and intesti-
nal secretions) as well as a cell-mediated immunoresponse 
(IL2 and IFNγ measured in the spleen).96
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PLA-b-Pluronic-b-PLA NPs are highly biodegradable 
and biocompatible and could represent an interesting poten-
tial drug-delivery option. In a recent study, these carriers 
were synthesized from commercially available Pluronic P85 
and biodegradable PLA. The NPs were fully characterized 
(mean diameter of about 170 nm) before being analyzed for 
toxicity in a Kunming mouse model (~30 g). The animals 
were exposed to 8, 40, or 200 µg/animal of empty nanocar-
riers for a period of 28 days via oral gavage. The authors 
did not observe any behavioral, clinical, biochemical, or 
histological toxicity in the heart, liver, or kidneys at any of 
the doses investigated. However, it should be stated that the 
doses utilized in the study were rather low for oral exposure; 
therefore, a note of caution is required. This is of even more 
importance considering the study lacked biokinetic data.97
In a 2010 study, the toxicity and biodistribution of PLGA 
NPs with potential medical applications were assessed 
following oral delivery. Characterization data showed the 
NPs to be very polydispersed in solution with a size range 
of 300 nm to 1 µm. To investigate biodistribution and NP-
induced histopathology, female BALB/c mice (~20 g) were 
exposed to 4 mg of empty carriers via oral gavage on a 
single (24 hours) or repeated regime (every day for 5 days). 
The animals were killed on day 1, 5, and 7 posttreatment. The 
brain, heart, kidneys, liver, lung, spleen, intestines, pancreas, 
stomach, and thymus were collected from each animal. From 
the data, it was evident the particles accumulated predomi-
nantly in the liver at around 40% of the administered dose, 
followed by the kidneys (~30%), heart (~10%), and brain 
(~10%) throughout the exposure period. Finally, no signifi-
cant histopathological changes were noted for the NPs at the 
doses and time points investigated.98
The absorption and distribution of four rhodamine B 
isothiocyanate-incorporated silica oxide NPs with potential 
for medical applications was undertaken. The NPs were 
either 20 or 100 nm with a positive or negative charge. In 
these experiments, female athymic nude mice (~20 g) were 
orally exposed to NPs at a dose of 2 mg per animal. Whole-
body optical fluorescence imaging of mice demonstrated 
fluorescence signals mainly in the GIT. Additionally, ex 
vivo optical images of major organs from exposed mice 
showed distribution of the NPs to the lungs, liver, pancreas, 
and kidneys. NPs with a diameter of 20 nm showed higher 
uptake in the lungs compared to the larger particles. How-
ever, following oral administration of the silica NPs, no 
surface-charge-associated differences were observed in terms 
of translocation and distribution. Interestingly, at 10 hours 
postadministration, the majority of 20 nm NPs were cleared 
from the organs and detectable only in the kidneys. On the 
other hand, the 100 nm NPs were visualized mainly in the 
liver. Finally, the dissociation of rhodamine B isothiocyanate 
from the NPs was investigated in vitro in highly acidic con-
ditions (mimicking the low pH in the stomach [1.2]). It was 
noted that there was no release from the larger 100 nm NPs, 
whereas minimal dissociation of rhodamine B isothiocya-
nate was observed from the 20 nm NPs. This finding is best 
explained by the larger exposed surface area of the smaller 
NPs in the highly acidic surroundings.99
Currently, the only available management in food allergy 
is strict avoidance of the culprit food. However, in recent 
years, allergen immunotherapy has been investigated to 
protect food-allergic individuals from severe reactions.100 The 
strategy is based on continuous low-dose administration of 
the allergen to provide protection against the IgE-governed 
adverse responses to the allergen. In a recent study, polyan-
hydride NPs (150 nm) loaded with a peanut-protein extract 
(PE) were evaluated for oral immunotherapy potential in 
peanut-sensitized mice (CD1, ~20 g). The animals were 
sensitized by oral administration of a mixture of peanut butter 
and 5 µg cholera toxin on days 1, 7, 15, and 21. On days 25, 
28, and 35 the animals received a single oral dose of 1 mg 
PE, either suspended in purified water or incorporated in the 
NPs. Finally, on days 44 and 45, animals were challenged by 
an injection of 2 mg PE intraperitoneally, in order to incite 
an anaphylactic shock in the sensitized animals. Anaphylaxis 
was evaluated by means of symptom scores and mast-cell 
protease 1 levels. The data demonstrated that 20 minutes 
after challenge, piloerection and cyanosis were similar for 
animals treated with either PE or PE-NPs. Moreover, animals 
from the unsensitized group were found completely static 
with a high difficulty for simple movement, whereas treated 
animals were able to move or react against pain or pressure. 
Moreover, PE-NP treatment was associated with significantly 
lower levels of mast-cell protease 1 and a significantly higher 
survival rate after challenge.100 Table 1 summarizes all the 
studies highlighted in this review, their intended medical 
application, and therapeutic activity.
Summarizing remarks
For a successful oral nanodelivery platform, the system must 
allow for efficient transport of the NP–drug complex or the 
drug alone following release from the NP to the desired 
destination, with intestinal epithelial cells being extremely 
important in the efficacy of transport of orally adminis-
tered drugs into systemic circulation. In general, hydro-
phobic high-molecular-weight drugs are relatively poor at 
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Nanodelivery or stabilized solid-drug NPs for oral administration
constituents developed in drug discovery programs have 
poor aqueous solubility and are thus considered unsuitable 
for clinical testing.106 If the rate of dissolution of the drug 
is significantly slower than the rate of absorption, then dis-
solution of the drug is considered the rate-limiting step and 
the formulation might not necessarily be a viable candidate 
as an effective oral medicine. Furthermore, it has been sug-
gested that drug dissolution in intestinal fluid is required to 
allow partitioning of drug molecules across the epithelial 
cell membrane through passive diffusion.107 As touched upon 
and highlighted in numerous studies, the molecular size of 
drugs significantly influences their permeation ability through 
biological membranes. To overcome (at least partially) the 
various limitations discussed herein, nanoformulations are 
being developed to enable the stimuli-responsive release of 
drugs (eg, pH, temperature, light) by combining advance-
ments in materials chemistry. Due to all the aforementioned 
complications, to date only a handful of oral nanoformula-
tions are commercially available. These include Emend (anti-
emetic, US Food and Drug Administration [FDA] approval 
2003), Rapamune (organ rejection, FDA approval 2002), 
Tricor (lipid regulation, FDA approval 2004), Megace ES 
(anorexia and cachexia, FDA approval 2005), and Renagel 
(chronic kidney disease, FDA approval 2000).108
Toxicological considerations
In a physiological environment, NPs acquire a new identity, 
which might alter their size, surface charge, and aggre-
gation, along with a constantly changing and devolving 
deposited protein corona. It is noteworthy that a particle’s 
acquired biological identity can be dramatically different 
from the material designed in the laboratory. The biological 
attributes afforded by the corona can affect physiological 
and toxicological responses to nanoformulations in vivo. 
Both the required medical and toxic effects of nanosize 
delivery systems are fundamentally governed by their 
physicochemical characteristics, including their bioavail-
able surface area, specific surface properties (eg, chemistry 
and charge), solubility, and shape.109 These factors influence 
their ability to enter and deposit in tissue that might be inac-
cessible to larger counterparts.110 Furthermore, nanocarriers 
can alter the physicochemical properties of the cargo drugs, 
peptides, and genes, as well as altering the solubility and 
pharmacokinetic disposition upon delivery compared to 
unmodified drugs.24,34,48,55,66 Therefore, orally administered 
nanomedicines can be potentially hazardous to human health 
(the need to address the balance between improved delivery/
efficacy and potential nanotoxicity). These adverse effects are 
penetration of GIT physical barriers, leading to lower systemic 
bioavailability.101 Moreover, microfibrils between two epithe-
lial cells provide a tight junction, also acting as a physical bar-
rier for orally administered formulations.102 Furthermore, the 
presence of a multitude of metabolic enzymes (eg, proteases/
peptidases, trypsin, chymotrypsin, elastase, carboxypepti-
dases) and the acidic environment of the stomach can affect 
the drug and/or NPs. Another principal problem for oral 
nanomedicines is the phenomenon of first-pass metabolism in 
the liver, which causes the therapeutic to be metabolized and 
changed extensively before reaching systemic circulation.103 
As highlighted, the GIT is an extremely complex system, with 
numerous barriers to a drug/dosage system, thereby affecting 
drug and NP stability, uptake, and thus bioavailability. From 
the literature, it is clear that emptying of gastric contents is an 
additional important factor in drug circulation and accounts 
for much of the variation in absorption. The ability to control 
the release of the prodrug would be highly advantageous to 
negate erratic drug absorption. It is important to note that 
due to the fast rate of gastric emptying, it is often difficult 
for the drug to achieve maximum absorption through the oral 
route.103 Factors that influence gastric emptying include but 
are not limited to when the last meal was consumed, the age 
and sex of the individual, and the nature of the specific meals 
consumed around the time that the medicine is administered.104 
It seems logical to consider the uptake mechanisms of a given 
formulation. For example, if the construct cargo is released 
in close proximity to the enterocytes, its uptake will involve 
the usual dietary absorption mechanisms and the drug will be 
transported directly to the liver via the portal vein. An alter-
native physiological route of transport could be the gut’s 
lymphatic vessels. These vessels link to the mesenteric lym-
phatic network, and any material in the lymphatic systemic 
will ultimately end up in the systemic blood circulation. This 
direct-uptake route for nanoconstructs and their transport to 
gut-associated lymphatic tissue could potentially be advanta-
geous for oral drug-delivery approaches.
In addition to the physiologically harsh environment 
and the formidable physical barriers of the GIT, there are a 
number of important physicochemical/pharmaceutical factors 
attributed to the drug itself that further influence the perme-
ability and bioavailability of a nanoformulation. The first 
of these limiting factors is the solubility of the formulation 
at a physiologically relevant pH.105 Unsurprisingly, highly 
soluble drugs are not associated with bioavailability issues. 
However, low/poor bioavailability is common with orally 
administered forms of hydrophobic and slowly absorbed 
drugs. It has been reported that up to 50% of all new chemical 
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principally caused by the nanoparticulate delivery directly 
interacting with biological surroundings or as a result of 
unwanted bioaccumulation in the case of insoluble carriers. 
Interestingly and importantly, from a toxicological perspec-
tive, in the majority of studies that were scrutinized in this 
review, safety evaluation was either entirely lacking for the 
manufactured formulation or toxicity testing was restricted 
to simple in vitro models or acute in vivo studies. This might 
be one of the reasons that despite considerable therapeutic 
promise demonstrated by many of the manufactured nano-
constructs in experimental settings, the use and translation 
of nanomedicines from laboratory to clinical settings have 
been extremely slow. It is imperative that appropriate and 
comprehensive risk-reduction strategies be devised and 
incorporated for all materials proposed for medical applica-
tions. To address this issue, the development of risk-assess-
ment frameworks that address the toxicological potential of 
nanomedicines is of crucial importance (ie, H2020 project 
BIORIMA). Any preclinical toxicological assessment should 
include in vitro and in vivo long-term physiologically rel-
evant exposure of the delivery formats, although this would 
have to be tailored and designed to take into account the 
intended therapeutic application of the medicine. Currently, 
the majority of toxicological strategies are influenced by route 
of delivery rather than mode of action.
It is also important to acknowledge that it is extremely 
difficult to fully understand how a given material/formulation 
behaves in the gut or evaluate its potential toxicity in the 
GIT in vivo. Nevertheless, bioaccumulation/biokinetics and 
toxicity assessment of the vehicle/prodrug in target organs 
is very possible. As touched upon, it is worth reiterating that 
is very possible that hazardous nanomedicines may have 
been effectively screened out in research than preceded the 
current preclinical investigations in animal models discussed 
in this review.
Other considerations
It is important to recognize that rodents have a different 
metabolism than humans and might exhibit a different 
metabolic rate compared with humans for certain drugs 
(eg, rats have a higher metabolic clearance of Efv compared 
to humans). These interspecies differences must be consid-
ered in the evaluation of the pharmacokinetic benefits and 
toxic potential of given formulations.111 As an additional 
complication, nanocarriers can alter the physicochemical 
properties of a variety of drugs, peptides, genes, and phar-
maceutical changes in stability, solubility, and pharmacoki-
netic disposition can occur upon delivery, which need to be 
considered.
Future perspectives
The utilization of nanomedicines in conjunction with 
biological systems – namely solid drug NPs, drugs, proteins, 
and DNA – has the potential to have an outstanding impact 
in treating various diseases, as well as various applications 
in tissue regeneration, biological sensors, and drug delivery. 
Additionally, combinations of imaging and therapeutic agents 
incorporated into the same nanoformulation will undoubt-
edly be beneficial in the future. Considerable efforts have 
been to ameliorate the bioavailability-related issues of oral 
drug delivery and increasing therapeutic efficacy, which 
will hopefully in time result in improved end-user compli-
ance. The literature clearly demonstrates the potential of 
nanosize carrier systems over traditional approaches (at the 
molecular level) for oral delivery. Among the most success-
ful of such approaches are the development of nanocrystals, 
nanoemulsions, and polymeric NPs. In addition, interest in 
self-emulsifying drug-delivery systems, dendrimers, and 
micelles is increasing.
Overcoming the physical barriers in the GIT is a signifi-
cant hindrance to the successful design of nanostructures for 
the oral route of administration. To this end, modification of 
particle-size distribution and surface area is a critical parameter 
in terms of the capacity of NPs to interact with the intestinal 
mucosa. It is crucial that nanoformulations are stable in bio-
logical fluids (particularly in the acidic microenvironment 
of the stomach) to avoid the premature release of cargo and 
unwanted toxic effects. The surface chemical composition 
will undoubtedly influence the stability of the nanocarrier, 
as well its interaction and transport across the epithelial bar-
rier. Finally, the specific targeting/affinity of the nanomedi-
cine for membrane receptors may be beneficial (although 
principally difficult) in overcoming the biological barriers.
Despite the plethora of advantages that nanomedicine 
offers, systems still have limitations, one of which is poten-
tial to affect human health adversely, which needs to be 
thoroughly addressed and is still regarded as an afterthought 
in the majority of studies scrutinized in this review. A wide 
array of complex issues involving physiological, physico-
chemical, and molecular processes need to be considered 
for a better understanding of potential clinical toxicities of 
nanomedical formulations. It might sound obvious, but nano-
medical preparations with great potential in animal models 
require further assessment in human clinical testing, which is 
associated with its own set of challenges. In addition, clini-
cal translational studies, including pharmacokinetic profiles 
and long-term toxicity, should be performed to address 
fundamental questions in regard to the clinical feasibility of 
oral nanomedicine.
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